DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  1 
CONFIDENTIAL  
 A Controlled Human Infection Study of Influenza 
A/Bethesda/MM2/H1N1 Virus (A/California/04/2009/H1N1- like) in 
Healthy Subject s to Assess the Effect of Pre -Existing Immunity on 
Symptomatic Influenza Virus Infection  
DMID Protocol Number:  18-0010 
DMID Funding Mechanism:  Vaccin e and Treatment Evaluation Units  
IND Sponsor: Division of Microbiology and Infectious Diseases (DMID) , National Institutes 
of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)  
Lead Pr incipal Investigator: Kathleen Neuzil, MD, MPH  
DMID Clinical Project Manager: Kathy Ormanoski , MS   
 
Version Nu mber:  3.0 
04 November  2020  
 
 
 
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  2 
CONFIDENTIAL  
 STATEMENT OF ASSURANCE  
Each Institution will hold a current Federal Wide Assurance (FWA) issued by the Office of 
Human Research Protections (OHRP) for federally -funded human subjects research. Each FWA 
will designate at least one Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) registered with OHRP, for which  the research will be reviewed  and approved by the 
IRB/IEC and will be subject to continuing review [45 CFR 46.103(b)]. The IRB/IEC designated 
under an FWA may include an institution’s IRB/IEC, an independent IRB/IEC, or an IRB/IEC of another institution  after establishing a written agreement with that other institution.  
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  3 
CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
The study will be carried out in accordance with Good Clinical Practice (GCP)  and as required 
by the following:  
• United States (US) Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects  
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50  
(Protection of Human Subjects) , 21 CFR Part 54 (Financial Disclosure by Clinical 
Investigators) , 21 CFR Part 56 (Institutional Review Boards) , 21 CFR  Part 11, and 21 
CFR Part 312  (Investigational New Drug Application), 21 CFR 812 (Investigational 
Device Exemptions)  
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
for Human Use (ICH): Good Clinical Practice (GCP) E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry,” published in the Federal 
Register (83 Federal Register 8882 (2018)  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving 
Human Subjects, a s applicable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , 
as applicable  
• Applicable Federal, State, and Local Regulations and Guidance  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  4 
CONFIDENTIAL  
 SIGNATURE PAGE  
The signature below provides the necessary assurance that this study will be conducted 
according to all stipulations of the protocol, including all statements regarding confidentiality, 
and according to local legal and regulatory requirements and applicabl e US federal regulations 
and ICH E6 GCP  guidelines.  
I agree to conduct the study in compliance with GCP and applicable regulatory requirements.  
I agree to conduct the study in accordance with the current protocol and will not make changes to the protocol without obtaining the Sponsor’s approval and IRB/IEC approval, except when 
necessary to protect the safety, rights, or welfare of subjects.  
Site Investigator  Signature : 
 
Signed:   Date:   
 Name 
Title   
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  5 
CONFIDENTIAL  
 TABLE OF CONTENTS  
STATEMENT OF ASSURANCE ....................................................................................................... 2  
STATEMENT OF COMPLIANCE  .................................................................................................... 3  
SIGNATURE PAGE  ............................................................................................................................ 4  
TABLE OF CONTENTS  ..................................................................................................................... 5  
LIST OF TABLES .............................................................................................................................. 10 
LIST OF FIGURES  ............................................................................................................................ 11 
LIST OF ABBREVIATIONS  ............................................................................................................ 12 
PROTOCOL SUMMARY  ................................................................................................................. 16 
 KEY ROLES  ............................................................................................................................. 23 
 BACKGROUND AND SCIENTIFIC RATIONALE  ............................................................ 25 
 Background  ..................................................................................................................... 25 
 Scientific Rationale ......................................................................................................... 27 
2.2.1  Purpose of Study................................................................................................ 27 
2.2.2  Study Population ............................................................................................... 30 
 Potential Risks and Benefits  .......................................................................................... 30 
2.3.1  Common Symptoms of Influenza Illness  ......................................................... 30 
2.3.2  Potential Risks  ................................................................................................... 31 
2.3.3  Potential Benefits ............................................................................................... 33 
 STUDY OBJECTIVES AND OUTCOME MEASURES  ...................................................... 34 
 STUDY DESIGN  ...................................................................................................................... 35 
 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  ........................................... 38 
 Study Product Description ............................................................................................. 38 
5.1.1  Formulation, Packaging, and Labeling  ............................................................ 38 
5.1.2  Product Storage and Stability  ........................................................................... 38 
 Acquisition/Distribution  ................................................................................................. 39 
 Dosage/Regimen, Preparation, Dispensing and Administration of Study 
Intervention/Investigational Product  ........................................................................... 39 
 Pre-determined Modification of Study Intervention/Investigational Product for an 
Individual Subject  ......................................................................................................... 40 
 Accountability Procedures for the Study Intervention/Investigational Product(s)  ..... 40 
 SELECTION OF SUBJECTS AND STUDY ENROLLMENT AND WITHDRAWAL .... 42 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  6 
CONFIDENTIAL  
 
 Eligibility Criteria  ........................................................................................................... 42 
6.1.1  Subject Inclusion Criteria .................................................................................. 42 
6.1.2  Subject Exclusion Criteria  ................................................................................ 44 
 Withdrawal from the Study, Discontinuation of Study Product, or Study Termination
........................................................................................................................................ 47 
6.2.1  Discontinuation of the Study Product  .............................................................. 47 
6.2.2  Subject Replacement  ......................................................................................... 47 
6.2.3  Study Termination  ............................................................................................. 47 
6.2.4  Withdrawal during the Inpatient Period ........................................................... 47 
6.2.5  Withdrawal during the Follow -up Period ........................................................ 48 
6.2.6  Reasons for withdrawal might include, but are not limited to the following:
 ............................................................................................................................ 48 
 STUDY PROCEDURES  .......................................................................................................... 50 
 Screening Period  ............................................................................................................. 50 
7.1.1  Study Visit 00A (Day -30 to -3) ....................................................................... 50 
 Inpatient Period  ............................................................................................................... 51 
7.2.1  Study Visit 00B (Day -2) .................................................................................. 51 
7.2.2  Study Visit 00C (Day -1) .................................................................................. 52 
7.2.3  Study Visit 01 (Day 1) Before Challenge  ........................................................ 53 
7.2.4  Study Visit 01 (Day 1) Post -challenge  ............................................................. 53 
7.2.5  Study Visit 02 (Day 2)  ...................................................................................... 54 
7.2.6  Study Visit 03 (Day 3)  ...................................................................................... 54 
7.2.7  Study Visit 04 (Day 4)  ...................................................................................... 55 
7.2.8  Study Visit 05 (Day 5)  ...................................................................................... 56 
7.2.9  Study Visit 06 (Day 6)  ...................................................................................... 56 
7.2.10  Study Visit 07 (Day 7)  ...................................................................................... 57 
7.2.11  Study Visit 08 (Day 8)  ...................................................................................... 57 
7.2.11.1  Unscheduled Inpatient Days After Day 8  .......................................... 59 
 Follow -up Period ............................................................................................................ 60 
7.3.1.1  Post-discharge (Approximately Day 9 to Day 14)  ............................ 60 
7.3.1.2  Study Visit 09 (Day 15 ± 3 Days)3Days  ............................................ 60 
7.3.1.3  Study Visit 10 (Day 29 ± 3 Days)  ...................................................... 60 
7.3.1.4  Study Visit 11 (Day 61 ± 5 Days)  ...................................................... 61 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  7 
CONFIDENTIAL  
 7.3.2  Final Study Visit -- Telephone Follow -up (Day 91 ± 7 Days)  ....................... 61 
 Early Termination Visit  .................................................................................................. 61 
 Unscheduled Study Visits  .............................................................................................. 62 
 Protocol Deviations  ........................................................................................................ 62 
 DESCRIPTION OF CLINICAL AND LABORATORY EVALUATIONS  ........................ 64 
 Clinical Evaluations  ........................................................................................................ 64 
8.1.1  Research Procedures  ......................................................................................... 65 
8.1.2  Assessment of Concomitant Medications/Treatments other than Study 
Product  ............................................................................................................... 66 
8.1.3  Assessment of Subject Compliance with Study Intervention/Investigational Product/Investigational Device ......................................................................... 66
 
8.1.4  Non-Research Standard of Care ....................................................................... 67 
8.1.5  Non-Research Standard of Care ....................................................................... 67 
 Laboratory Evaluations  .................................................................................................. 67 
8.2.1  Clinical Laboratory Evaluations  ....................................................................... 67 
8.2.2  Research Assays  ................................................................................................ 68 
8.2.2.1  Laboratory Specimen Preparation, Handling, and Storage  ............... 68 
8.2.2.2  Laboratory Specimen Shipping  .......................................................... 68 
 ASSESSMENT OF SAFETY  .................................................................................................. 69 
 Assessing and Recording Safety Parameters  ................................................................ 69 
9.1.1  Adverse Events (AEs)  ....................................................................................... 69 
9.1.1. 1 Adverse Events Grading ...................................................................... 70 
9.1.2  Serious Adverse Events (SAEs)  ....................................................................... 73 
 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  ......................................................................................... 74 
 Specification of Safety Parameters  ................................................................................ 74 
 Reporting Procedures  ..................................................................................................... 74 
9.4.1  Reporting Serious Adverse Events  ................................................................... 74 
9.4.2  Regulatory Reporting for Studies Conducted Under DMID Sponsored- IND ............................................................................................................................ 75
 
9.4.3  Reporting of Pregnancy ..................................................................................... 75 
 Type and Duration of Follow -up of Subjects after Adverse Events ............................ 76 
 Halting Rules ................................................................................................................... 76 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  8 
CONFIDENTIAL  
 9.6.1  Study Halting Criteria  ....................................................................................... 76 
 Safety Oversight  ............................................................................................................. 76 
9.7.1  Safety Monitoring Committee (SMC)  ............................................................. 76 
 HUMAN SUBJECTS PROTECTION  .................................................................................... 78 
 Institutional Review Board/Independent Ethics Committee  ........................................ 78 
 Informed Consent Process .............................................................................................. 78 
 Consent for Future Use of Stored Specimens and Data  ............................................... 80 
 Exclusion of Women, Minorities, and Children (Special Populations)  ...................... 81 
 Subject Confidentiality  ................................................................................................... 81 
 Certificate of Confidentiality  ......................................................................................... 82 
 Costs, Subject Compensation, and Research Related Injuries  ..................................... 82 
 STATISTICAL CONSIDERATIONS ..................................................................................... 83 
 Introduction  ..................................................................................................................... 83 
 Study Hypotheses  ........................................................................................................... 83 
 Sample Size Considerations  ........................................................................................... 83 
11.3.1  Study Design ...................................................................................................... 83 
11.3.2  Sample Size ........................................................................................................ 83 
 Planned Interim Analyses ............................................................................................... 84 
11.4.1  Interim Safety Review ....................................................................................... 85 
 Final Analysis Plan  ......................................................................................................... 85 
11.5.1  Analysis Populations  ......................................................................................... 85 
11.5.2  Safety and Clinical Data  ................................................................................... 86 
11.5.3  Immunological Data  .......................................................................................... 87 
11.5.1  Transcriptomic Data  .......................................................................................... 88 
11.5.2  Genomics Data ................................................................................................... 88 
11.5.3  Missing Values and Outliers  ............................................................................. 88 
 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .............. 89 
 QUALITY CONTROL AND QUALITY ASSURANCE  ..................................................... 90 
 DATA HANDLING AND RECORD KEEPING ................................................................... 91 
 Data Management Responsibilities  ............................................................................... 91 
 Data Coordinating Center/Biostatistician Responsibilities  .......................................... 91 
 Data Capture Methods  .................................................................................................... 91 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  9 
CONFIDENTIAL  
 
 Types of Data  .................................................................................................................. 92 
 Study Records Retention  ................................................................................................ 92 
 CLINICAL MONITORING  ..................................................................................................... 93 
 PUBLICATION POLICY  ........................................................................................................ 94 
 LITERATUR E REFERENCES  ............................................................................................... 95 
 APPENDICES  ........................................................................................................................... 99 
 Schedule of Events  ............................................................................ 100 
 Venipuncture Volumes (mL)  ............................................................ 104 
 High -Risk Medical Conditions for Severe Influenza  ...................... 106 
 Flu-PRO Survey Instrument and Validation Diary ......................... 107 
 
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  10 
CONFIDENTIAL  
 LIST OF TABLES  
 
Table 1:  Study Objectives and Outcome Measures ..................................................................... 17 
Table 2:  Study Intervention  .......................................................................................................... 21 
Table 3: Doses Used in Previous Challenge Studies in Humans Since 1985  ............................ 28 
Table 4:  Dose Escalation Results with A/Bethesda/MM2/H1N1 challenge strain  ................... 30 
Table 5:  Study Intervention Regimen  .......................................................................................... 40 
Table 6: Clinical Laboratory Normal Ranges  .............................................................................. 46 
Table 7:  Severity Grading for Oral Temperature  ........................................................................ 71 
Table 8:  Pulse and BP Adverse Event Grading ........................................................................... 71 
Table 9:  Clinical Safety and Laboratory AEs Grading ............................................................... 72 
Table 10:  Power to detect odds ratios (OR) for a one SD increase in a continuous, 
normally distributed covariate in a logistic regression model at the α=0.05-
level  ................................................................................................................................. 84 
Table 11:  Probability (%) of observing at least one safety event, given varying underlying event probabilities and group sizes  ............................................................. 84
 
Table 12:  Schedule of Events  ....................................................................................................... 100 
Table 13:  Venipuncture Volumes (all volumes are approximate)  .............................................. 104 
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  11 
CONFIDENTIAL  
 LIST OF FIGURES  
Figure 1:  Schematic of Study Design ............................................................................................ 22 
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  12 
CONFIDENTIAL  
 LIST OF ABBREVIATIONS  
°C Degree Celsius  
°F Degree Fahrenheit  
ADL  Activities of Daily Living  
AE Adverse Event/Adverse Experience  
ALP  Alkaline Phosphatase  
ALT  Alanine Transaminase  
ANC  Absolute Neutrophil Count  
ASC  
AST  Antibody Secreting Cells  
Aspartate Transaminase  
BMI  Body Mass Index  
BP Blood Pressure  
BUN Blood Urea Nitrogen  
CBC Complete Blood Count  
CFR  Code of Federal Regulations  
CHI Controlled Human Infection  
CK Creatinine Kinase  
Cl Chloride  
cMRI  Cardiac MRI  
CMS  Clinical Material Services  
CO 2 Carbon Dioxide  
CoP Correlation of Protection  
COPD  Chronic Obstructive Pulmonary Disease  
Cr Creatinine  
CRF Case Report Form  
CXR Chest X -Ray 
DBP Diastolic Blood Pressure  
DCC Data Coordinating Center  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, 
NIH, DHHS  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  13 
CONFIDENTIAL  
 DSMB  Data and Safety Monitoring Board 
ECG  Electrocardiogram  
eCRF Electronic Case Report Form  
eGFR  Estimated Glomerular Filtration Rate  
ELISA  Enzyme -linked Immunosorbent Assay  
EPT End Point Titers  
ER Emergency Room  
FDA  Food and Drug Administration  
Flu-PRO  Survey Instrument  Influenza Patient Reported Outcome  
FWA  Federal Wide Assurance 
GCP Good Clinical Practice  
g/dL  Grams per Deciliter  
GMFR  Geometric Mean Fold Rise  
GMP  Good Manufacturing Practice  
GMT  Geometric Mean Titer  
H1N1pdm09  A/California/04/2009 (H1N1) -like Influenza A Virus  
HA Hemagglutinin  
HAI Hemagglutinin Inhibition Test  
HBV Hepatitis B Virus  
HCV Hepatitis C Virus  
HIV Human Immunodeficiency Virus  
HR Heart Rate  
iADL  Instrumental Activities of Daily Living  
ICF Informed Consent Form  
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use  
ICU Intensive Care Unit  
IDE Investigational Device Exemption  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  14 
CONFIDENTIAL  
 IV Intravenous  
K Potassium  
Kg/m2 Kilogram per Square Meter  
LAR  Legally Authorized Representative  
LDH  Lactate Dehydrogenase  
LID Laboratory of Infectious Diseases at NIAID  
M Molar  
MAD  Mucosal Atomization Device  
mg Milligram  
mg/dL  Milligrams per Deciliter  
mL Milliliter  
mm Millimeter  
mm3 Cubic Millimeter  
mm Hg  Millimeter of Mercury  
MMID  Mild -to-Moderate Influenza Disease  
MN Microneutralization  
MOP  Manual of Procedures  
MRI  Magnetic Resonance Imaging  
N Number (typically refers to subjects)  
Na Sodium  
NA Neuraminidase  
NAI Neuraminidase Inhibition 
NIAID National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
NLF  Nasal Lavage Fluid  
NP Nasopharyngeal  
NSAID  Non-Steroidal Anti-inflammatory Drug 
OHRP  Office for Human Research Protections  
PBMC  
PE Peripheral Blood Mononuclear Cells  
Physical Exam  
PI Principal Investigator  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  15 
CONFIDENTIAL  
 PT Prothrombin Time  
PTT Partial Thromboplastin Time  
QA Quality Assurance  
QC Quality Control  
REDCap Research Electronic Data Capture  
RR Respiratory Rate  
RT-PCR  Reverse Transcript ion – Polymerase Chain Reaction  
SAE  Serious Adverse Event/Serious Adverse Experience  
SBP Systolic Blood Pressure  
SE Standard Error  
sIgA Secretory Immunoglobulin A  
SMC  Safety Monitoring Committee  
SpO 2 Saturation of Peripheral Oxygen  
TCID 50 Median Tissue Culture Infective Dose  
THC  Tetrahydrocannabinol  
UA Uric Acid  
ULN  Upper Limit of Normal 
US United States  
VTEU  Vaccin e and Treatment Evaluation Units  
WBC  
wt White Blood Cell  
Wild -type  
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  16 
CONFIDENTIAL  
 PROTOCOL SUMMARY  
Title:  A Controlled Human  Infection Study of Influenza 
A/Bethesda/MM2/H1N 1 Virus (A/California/04/2009/H1N1-
like) in Healthy Subject s to Assess the Effect of Pre -Existing 
Immunity on Symptomatic Influenza Virus Infection. 
Phase:  1 (Controlled human infection study)  
Population:  Up to 80 healthy adult subjects between the ages of 18 to 49 
years of age inclusive , who are in good health and meet 
eligibility criteria .  
Number of Sites:  Four domestic vaccin e and treatment evaluation unit (VTEU) 
sites.  
Study Duration:  Approximately 180 days (from time of study activation to last 
subject’s last study day).  
Subject Participation 
Duration:  Approximately 120 days.  
Estimated Time to 
Complete Enrollment:  Approximately 60 days 
Description of Study 
Product:  Influenza A/Bethesda/MM2/H1N1 virus at a total dose of 2 mL 
of approximately 5x106/mL tissue culture infective dose 
(TCID 50). 
• Route of administration: Intranasal  
• Volume: 1 mL per nostril (2 mL dose total)  
Design of the Study:  This is a study of a reverse -engineered, GMP grade, antiviral -
sensitive, influenza A/Bethesda/MM2/H1N1 virus 
(A/California/04/2009/H1N1-like) infection to assess the effect of pre -existing immunity on clinical and immunological 
responses. Up to 80 healthy adult subjects will undergo intranasal inoculation with A/Bethesda/MM2/H1N1 virus, and their clinical manifestations, viral shedding and immunological 
responses will be characterized.  
 
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  17 
CONFIDENTIAL  
 Table 1: Study Objectives and Outcome Measures  
Primary Objective  Primary Outcome Measure  
• To evaluate the association of 
symptomatic RT-PCR -positive 
influenza virus infection post -
challenge and pre -existing HAI 
antibody titers  • Baseline A/Bethesda/MM2/H1N1 
hemagglutination inhibition (HAI)  antibody 
GMT association with development of MMID 
post-challenge, with MMID defined as 
presence of both of the following assessed 
through Day 8:  
1. Viral shedding detected by any approved positive RT-PCR test from NP swab, and 
2. Any one or more of the following 
symptoms or signs or laboratory findings, 
as related to the study agent; Arthralgia, 
Chest tightness, Chills, Conjunctivitis, Nasal congestion, Sinus Congestion, 
Coryza, Decreased appetite, Diarrhea, Dry 
Cough, Dyspnea/Shor tness of Breath, 
Fatigue/Tiredness, Fever (>38.0°C), 
Headache, Lymphopenia (<1000 cells/mL), 
Myalgia, Nausea, Oxygen Saturation Decrease by ≥3% from baseline, 
Productive Cough, Rhinorrhea, Sore Throat, and Sweats.  
Secondary Objectives  Secondary Outcome M easures  
• To describe viral recovery by 
quantitative RT-PCR from study subjects at baseline and post -challenge  • Frequency, timing, magnitude, and duration of 
viral shedding in NLF or NP swab collected 
daily using quantitative RT -PCR from baseline 
(Day -2 or -1 ) and daily from Day 2 through 
Day 8  
• To describe serum HAI and MN 
antibody responses post -challenge in 
healthy subjects by infection status  • Baseline and post -challenge HAI and MN  
antibody GMTs from serum measured at 
baseline (Day -2) and at Days, 8, 29, and 61 by 
infection status (RT-PCR-confirmed symptomatic, RT-PCR -confirmed 
asymptomatic, RT-PCR -negative 
symptomatic)  
• Percentage of healthy subjects achieving HAI  
and MN seroconversion (def ined as either a 
pre-challenge titer <1:10 and a post -challenge 
titer ≥1:40 or a pre -challenge titer ≥1:10 and a 
minimum four -fold rise in post -challenge 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  18 
CONFIDENTIAL  
 antibody titer) from serum measured at 
baseline (Day -2) and on Days 8, 29, and 61  
• To evaluate the as sociation of 
asymptomatic RT-PCR -positive 
influenza virus infection (viral 
shedding) post -challenge and pre -
existing HAI antibody titers  • Baseline A/Bethesda/MM2/H1N1 HAI  
antibody GMT measured at baseline (Day -2) 
association with asymptomatic viral sheddin g 
by RT -PCR through Day 8  
• To evaluate the association of 
symptomatic RT-PCR -negative status 
post-challenge and pre -existing HAI 
antibody titers  • Baseline A/Bethesda/MM2/H1N1 HAI  
antibody GMT measured at baseline (Day -2) 
association with development of any Flu-PRO 
symptoms post -challenge without influenza 
virus detection through Day 8  
• To determine the frequency of serious 
adverse events (SAE) post -challenge  • Frequency of serious adverse events (SAE) 
post-challenge through the inpatient stay  
• Frequency of serious adverse events (SAE) 
post- inpatient discharge  through the duration 
of the study (approximately three months post -
challenge)  
Exploratory Objectives  Exploratory Outcome Measures  
• To describe serum NAI antibody 
responses post challenge in healthy 
subjects by infection status  • Baseline and post -challenge NAI antibody  
GMTs from serum measured at baseline (Day -
2) and at Days, 8, 29, and 61 by infection 
status (RT- PCR -confirmed symptomatic, RT -
PCR -confirmed asymptomatic, RT -PCR -
negative symptom atic) 
• Percentage of healthy subjects achieving NAI 
seroconversion (defined as either a pre-
challenge titer <1:10 and a post -challenge titer 
≥1:40 or a pre -challenge titer ≥1:10 and a 
minimum four -fold rise in post - challenge 
antibody titer) from serum meas ured at 
baseline (Day -2) and on Days 8, 29, and 61  
• To evaluate the association of 
symptomatic RT-PCR -positive 
influenza virus infection, asymptomatic RT-PCR -positive 
influenza virus infection (viral shedding only) and symptomatic RT -
PCR -negative illness and pre -existing 
neuraminidase inhibition (NAI) 
antibody titers  • Baseline A/Bethesda/MM2/H1N1 
neuraminidase inhibition (NAI) antibody GMT measured at baseline (Day -2) association with 
infection status through Day 8 by 
symptom/shedding status  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  19 
CONFIDENTIAL  
 • To evaluate mucosal sIgA immune 
response, at baseline and post -
challenge  • Positive, GMT and GMFR responses for 
A/Bethesda/MM2/H1N1 -specific sIgA, 
nonnormalized and normalized for total IgA 
content, in NLF at baseline (Day -2), and Days 
8, 29, and 61  
• To ev aluate serum and mucosal 
cytokine and chemokine responses at baseline and post -challenge  • Determine A/Bethesda/MM2/H1N1 induced 
cytokines and chemokines in serum at baseline (Day -2), and Days 2, 4, 6, 8, and 15 
• Determine A/Bethesda/MM2/H1N1 induced 
cytokines and chemokines in NLF by study 
arm at baseline (Day -2), and approximately on 
Days 2, 4, 6, 8, and 15 
• To assess the effects of age, sex, 
baseline antibody titers and prior 
receipt of seasonal influenza vaccine 
on symptomatic RT -PCR -positive 
influenza i nfection post -challenge  • Evaluate the association between baseline 
A/Bethesda/MM2/H1N1 hemagglutination inhibition (HAI) GMT, age, sex, and receipt of seasonal influenza vaccin e in the previous 
year, and the development of MMID post -
challenge through Day 8 by multivariate 
logistic regression  
• To compare the clinical features of 
symptomatic RT-PCR -positive and 
RT-PCR -negative illness post -
challenge  • Self-report of clinical symptoms and their 
severity as measured by component question in Flu-PRO Survey Instru ment by post -challenge 
day and infection status  
• To explore alternative case definitions 
for symptomatic RT -PCR -positive 
influenza virus infection  • The combination of symptoms and symptom 
severity as determined by self -report using the 
Flu- PRO instrument will be evaluated to 
develop clinical case definitions which optimize sensitivity, specificity, and both for 
influenza virus infection among subjects with 
evidence of RT -PCR -positive influenza virus 
infection post -challenge  
• To evaluate the plasmablast res ponse 
post-challenge  in a subset of study 
subjects  • Determine the kinetics of 
A/Bethesda/MM2/H1N1 -specific plasmablasts, 
their specific -antibody ( e.g., anti -H1, -N1 and - 
H1N1 virus) production and isotype ( e.g., IgG, 
IgA) using an enzyme-linked immunospot 
(ELISpot) assay in PBMCs on Days  4, 6, and 8 
in a subset of subjects  
• To describe systemic transcriptional 
responses post -challenge in a subset of 
study subjects  • Determine changes in peripheral blood gene 
expression profiling based  on sequencing on 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  20 
CONFIDENTIAL  
 Days 2, 4, 8, and 15 relative to baseline (Days -
2 and 1 pre -challenge)  in a subset of subjects  
• To describe mucosal and systemic 
human immune cells in blood and 
NLF at baseline and post -challenge in 
a subset of study subjects  • Determine t he frequency, duration, timing and 
phenotypic characteristics of immune cells in 
the blood of subjects at baseline (Day -2) and 
at approximately on Days 4, 6, 8, 15, 29, and 61 in a subset of subjects  
• Determine the frequency, duration, timing and 
phenotypic characteristics of immune cells in the NLF in subjects at baseline (Day -2) and 
Days 2, 4, 6 and 8 in a subset of subjects  
• To describe anti -HA-stalk antibody 
titer at baseline and post-challenge  • For HA -stalk specific response, the GMTs and 
GMFR to group 1 stem domains will be measured at baseline (Day -2), and at 
approximately on Days 29 and 61  
• To assess the association of human 
leukocyte antigen (HLA) class I and II 
alleles with clinical, immune and viral responses  • Determine the frequency of HLA c lass I and II 
allele s as measured by genetic testing.  
• To assess the association of subject HLA class 
I and II alleles with development of MMID 
post-challenge through Day 8, pre-existing 
immune status, and magnitude and breadth of 
the elicited immune respon ses post -challenge  
• To evaluate cellular immune response 
at baseline and post -challenge  • Summarize the data on systemic and mucosal 
cytokines and chemokines induced by 
challenge and define their possible role in the 
process by which influenza exposure leads to 
infection, disease outcomes, and seroconversion at baseline and daily through 
Day 8  
• Frequency of influenza -specific B cell subsets 
in circulation (PBMC) at baseline (Day -2), 
and at approximately on Days 6, 8, 15, 29 and 61 
• Magnitude of i nfluenza -specific T cell 
responses in circulation (PBMC) to conserved 
T cell epitopes and inactivated virus at baseline 
(Day -2), and at approximately on Days 4, 6, 8, 
15, 29, and 61  
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  21 
CONFIDENTIAL  
 Table 2: Study Intervention  
Sample size  Intervention  
80 Influenza A/Bethesda/MM2/H1N1 Challenge  Virus 2  mL of approximately 
5x106 TCID 50/mL   
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  22 
CONFIDENTIAL  
 Figure 1: Schematic of Study Design  
 
  
N = up to 80  
Challenge Dose:  
A/Bethesda/MM2/H1N1 
virus challenge at a 2 
mL dose of  5x106 
TCID 50/mL 
 
Screening for eligibility  
Day -30 to -3 
Day -2 
Enrollment:  
Eligible subjects admitted to the inpatient  unit. Baseline evaluations  performed.  
Confirm consent. T raining on Flu-PRO questionnaire  and Validation Diary. Baseline lab 
  
Day  -1 
Day 1  
Day 2 -7 
 Remain in the inpatient unit. Daily evaluations.  
Discharge (if discharge criteria are met)  
Day 8  
Up to Day  91 
 Follow Up  
Challenge  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  23 
CONFIDENTIAL  
 
 KEY ROLES  
 
Lead Principal 
Investigator:  
 
 
Site Principal  
Investigator ( Cincinnati ): 
 
 
Site Principal  
Investigator  (Duke): 
   
Site Principal  
Investigator (S LU): 
 
 
DMID Clinical Project 
Manager:  Kathleen M. Neuzil, MD, MPH  
Professor of Medicine and Pediatrics  
University of Maryland School of Medicine 
(410) 706-4946  
kneuzil@som.umaryland.edu  
 David Bernstein, MD, MA  
Professor, Pediatrics  
Cincinnati Children's Hospital Medical Center  
(513) 636-7682  
david.bernstein@cchmc.org  
 Chris Woods , MD, MPH  
Professor, Medicine and Global Health  
Duke University School of Medicine  
(919) 668- 7174  
chris.woods@duke.edu  
 
Daniel Hoft, MD, PhD  
Professor  
Saint Louis University School of Medicine  
(314) 977- 5500  
daniel.hoft@health.slu.edu  
 Kathy Ormanoski, MS  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  24 
CONFIDENTIAL  
 Division of Microbiology and Infectious Diseases  
NIAID, NIH  
5601 Fishers Lane, Room 8E37  
Bethesda, MD 20892-9825  
(240) 627-3 334 
Kathy.ormanoski@nih.gov  
  
HAI and  MN Antibody 
Assays Laboratory  
  Southern Research  Institute  
2000 9th Avenue South  
Birmingham, AL 35205  
 
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  25 
CONFIDENTIAL  
 
 BACKGROUND AND SCIENTIFIC RATIONALE  
 Background  
The high morbidity and mortality associated with both pandemic and seasonal influenza, the 
continued threat of highly pathogenic avian influenza infections, the development and global spread of antiviral resistance, and the inadequacy of current influenza vaccin es makes influenza a 
high research priority. Although prior influenza research has addressed numerous aspects of viral biology and pathogenesis, many questions remain unanswered.  Advancing basic, translational 
and clinical research on influenza will inform the development of new and improved diagnostics, 
therapeutics, and vaccin es [1]. 
The natural history, pathogenesis, and immunology of human influenza have not been well 
characterized and cannot be adequately studied in animal models. Even the best models such as 
those in pigs and ferrets, although useful, have demonstrated limitations in their relevance to human disease. Influenza human challenge models offer a unique opportunity to further study 
influenza pathogenesis and to overcome some of the limitations associated with animal models and/or natural history studies in humans . These models are conducted in a we ll-controlled  
challenge setting in which virus exposure, infection rate, virus shedding, and sampling are being 
monitored in real -time. Such parameters are challenging to control in a “real world” setting.  
Previous human challenge  studies conducted in the US during the 1970s, 1980s, and 1990s 
advanced our understanding of the natural history, clinical characteristics, and immune responses following infection [2-14] . Such studies were also used to assess the efficacy of vaccin es and 
were critical for advancing the clinical development of influenza antivirals. Although these studies have provided important information, their generalizability to current questions is li mited 
due to the scope of the studies, the scientific techniques that were available at the time, the 
evolution of circulating virus strains and population immunity, and advances in antiviral and vaccin e development [2-14] . 
Ensuring subject  safety is  a paramount concern for any clinical study, particularly human 
challenge studies. I n the early 2000s, influenza human challenge  studies in the US were stopped 
due to a clinical event occurring after a human challenge study that was investigating the use of 
the antiviral peramivir as a prophylactic agent [15]. The subject was a 21 -year -old, previously 
healthy man with no prior cardiac history. Following receipt of peramivir and infection with an 
influenza B challenge  strain, he had asymptomati c ECG changes (described as new T wave 
inversions of leads II, aVF, and v4-6) on day 4 of the study. Repeat ECG at day 15 had returned to baseline, and he had no cardiac symptoms or cardiac enzyme (CPK) elevation. He then 
traveled to Indonesia for 2 weeks and became ill with an upper respiratory infection. When he 
returned to the US, he had an echocardiography performed at 51 days post influenza challenge, 
since he had had initial ECG changes post -infection. The echocardiogram showed reduced 
ejection fraction, with left ventricular enlargement. The man remained asymptomatic. Over the next 5 months, repeat echocardiograms showed gradual improvement and return to normal ejection fraction. The cause of the dilated cardiomyopathy was not ascertained but deemed 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  26 
CONFIDENTIAL  
 unlikely to be due to the study drug and also deemed unlikely to be due to the challenge  virus 
[15, 16] .  
As a result of the  clinical event described above, influenza challenge studies  were not performed 
in the US for many years.  A large and thorough review of 56 different influenza challenge 
studies, conducted in 2008 [4], confirmed that infection from an influenza challenge  stock 
induced only mild disease, with one third of subjects  having a fever and one fifth of subjects  
developing lower respiratory symptoms. Previous influenza challenge  studies have demonstrated 
that the required dosing differs depending on the viral strain, subtype, and administration method 
(Table 3) [17]. Influenza challenge studies in Europe continued to be performed [18].  
Since 2012, the Laboratory of Infectious Diseases (LID) at NIAID has been working to re - 
establish a controlled  influenza A/H1N1 challenge  model in healthy subjects in the US.  The first 
dose -ranging study of 49 healthy subjects using a Good Manufacturing Practice (GMP) influenza 
A (H1N1pdm09) challenge  strain demonstrated that mild to moderate influe nza illness could be 
induced in 70% to 80% of healthy subjects and mimicked natural infection both clinically and 
immunologically [19]. Clinical symptoms of influenza occurred post-challenge  with doses 
ranging from 103 to 107 TCID 50 but were most prevalent at the 106 and 107 TCID 50 doses ( Table 
4).  
NIAID’s second challenge  study at LID using the H1N1 model evaluated anti -hemagglutinin 
(HA), anti -neuraminidase (NA) and anti -HA stalk antibodies as correlates of protection in H1N1 
influe nza illness in 74 healthy subjects, finding that while higher HAI titers are indicative of 
some protection, NAI titers may be more predictive of protection from influenza infection  and 
reduced disease  [20, 21]. These studies have led to a number of ongoing laboratory studies using 
samples collected to address questions of intra-host evolution, gene expression, and immune response, many of which are expected to be published in the coming months. In clinical studies 
the model is now being implemented to test new therapeutics and vaccin es ([STUDY_ID_REMOVED] and 
[STUDY_ID_REMOVED]).  This virus has been used in 3 published trials and 1 unpublished trial to date in 
approximately 400 participants. No significant safety issues have been identified, no severe or complicated cases of influenza have occurred, and no transmission events outside of the study have been observed [19, 20, 22] . 
These studies helped to define a clinical endpoint termed “ mild-to-moderate influenza disease” 
(MMID)  which included evidence of influenza A virus shedding by RT -PCR and any of a 
number of standardized signs, symptoms, and laboratory findings consistent with clinical 
influenza illness. MMID is assessed using a validated,  patient-reported outcome (PRO) measure 
to standardize assessment of influenza (flu) symptoms in cli nical research , i.e. Flu -PRO  Survey 
Instrument  [23]. MMID is defined as influenza A virus shedding plus any one or more of the 
following symptoms or signs: arthralgia , chest tightness,  chills , conjunctivitis , nasal congestion, 
sinus c ongestion, coryza,  decreased appetite , diarrhea, cough, dyspnea/shortness of breath, 
fatigue/tiredness , fever (>38.0°C), headache, lymphopenia (<1000 cells/mL) , myalgia , nausea, 
oxygen saturation decrease by ≥3% from baseline , rhinorrhea,  sore throat , and sweats. The 
license  agreement with Leidos Biomedical Research to use the Flu -PRO Survey Instrument 
requires that an additional Validation Diary  comprised of nine questions be completed by 
subjects and that  data from both instruments  be provided to Leidos for further Flu-PRO 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
DMID/NIAID/NIH  27 
CONFIDENTIAL  
 quantitative validation exercises. Both Flu -PRO Survey Instrument and the Validation Diary are 
in Appendix D . 
One of the key components and gap-filling measures in NIAID’s strategic plan for universal 
influenza vaccin e development  is to expand the capacity to conduct human challenge  studies 
with relevant influenza challenge viruses [1]. Human challenge models provide a powerful tool 
to assess prevention and treatment options for influenza in a shorter time frame, with a smaller 
number of subjects  and against a known virus strain. Due to the known time of  infection, they 
allow for targeted collection of clinical samples, including prior to infection and in short time frames following inoculation . Human challenge  models may be particularly useful  to evaluate 
novel infl uenza vaccin es that do not target the HA head region, and therefore cannot  be judged 
based on current regulatory criteria for current inactivated influenza vaccin es. Through 
collaboration with both other academic and industry partners, these models have an d will 
continue to serve as an important resource in the influenza research community.  
 Scientific Rationale  
2.2.1 Purpose of Study  
This proposed study will  establish a H1N1 influenza  virus  controlled human infection (CHI) 
model at the NIAID  Division of Microbiology and Infectious Diseases (DMID) -sponsored 
VTEU clinical study sites. The model has been developed and used by NIAID Division of 
Intramural Research . The proposed study will expand US research  capacity to perform influenza 
CHI studi es to advance the understanding of influenza pathogenesis  and novel vaccin e research 
and development.  
The scientific goal of this study is to conduct a n influenza CHI study in healthy adults  to 
evaluate the association of pre-existing HAI titers and the development of symptomatic RT -
PCR -positive influenza virus infection. The study will build upon the NIH Clinical Center’s 
influenza CHI model with influenza A/California/04/2009 (H1N1 )-like  virus [19] . A CHI of up 
to 80 healthy subjects will be performed using a total dose of approximately 1 x 107 TCID 50, 
which has been shown to induce 60% or higher rates of MMID  in individuals who had pre -
challenge HAI titers of ≤1:40 [19]. Additional study objectives will assess clinical 
manifestations, viral shedding and immunological responses to the  challenge virus.  
DMID Protocol 18- 0010 Version 3.0 
H1N1 Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
 28 
 Table 3: Doses Used in Previous Challenge  Studies in Humans Since 1985  
 
Reference  Dose 
(log 10 
TCID
50) Proportion of Subjects*  
Mean Peak Titer 
Virus Shed (log 10 
TCID 50 ± SE)  Mean Duration of 
Shedding (Days ± 
SE) Proportion of Subjects with  
Infected† Shedding 
Virus  Systemic 
Febrile 
Illness  Respiratory 
Illness  Lower 
Respiratory 
Illness‡ H1N1  A/California/10/78  
Treanor et al. (1987) 
[24] 
Treanor et al. (1990) 
[25] 
Clements et al.  (1986) 
[26]  
4.5 
4.5 
4.0  
8/9 
8/8 
11/15   
8/9 
8/8 
11/15   
1.98 
2.4±0.4  
3.8±1.6   
NR 
3.6±0.6  
6.8±1.5   
0/9 
2/8 
5/15  
5/9 
3/8 
3/15  
NR 
NR 
1/15 
A/Hong Kong/123/77  
Betts et al. (1985) [27]  
4.2  
15/16   
15/16   
4.2±2.1   
4.7±2.1   
8/16  
5/16  
NR 
A/Kawasaki/9/86  
Youngner et al.  (1994) 
[28] 
Hayden et al.  (1994) 
[29]  
7.0 
7.0  
NR 
16/16   
10/14  
16/16   
2.2±0.4  
2.8±0.5   
NR 
NR  
3/14 
1/16  
6/14 NR  
NR 
2/16 
A/Texas/1/85  
Sears et al.  (1988) [30]  
Sears et al.  (1987) [31]  
6.4 
6.7  
26/28  
20/22   
26/28  
18/22   
3.1±1.9  
3.0±1.9   
4.5±2.4  
3.5±1.7   
8/28 
5/22  
11/28  
9/22  
NR 
1/22 
A/Texas/91  
Hayden et al. (1996) 
[32]  
5.0  
26/26   
24/26   
3.2±2.1   
2 (0-6) §  
10/26   
21/26   
7/26 H3N2  A/Bethesda/1/85  
Treanor et al.  (1990) 
[25] 
Sears et al. (1988) [30] 
Reuman et al.  (1989) 
[33]  
4.5 
7.0 
7.1  
5/5 
10/10  
18/19   
4/5 
10/10  
18/19   
2.4±0.6  
4.2±1.4  
3.5±0.5   
3.0±1.0  
5.9±1.3  
6.5  
2/5 
3/10 
NR  
2/5 
1/10 11/19   
NR 
NR 
NR 
A/England/40/83  
Al-Nakib et al.  (1986) 
[34]  
4.1  
31/31   
30/31   
4.0  
NR  
NR  
17/31   
NR 
A/Korea/1/82  
Snyder et al.  (1988) [35]  
6.0  
12/14   
12/14   
3.4±0.5   
5.1±0.3   
1/14  
5/14  
NR 
A/Los Angeles/2/87  
Clements et al.  (1992) 
[36]  
7.0  
22/24   
16/24   
1.5±0.3   
2.6±0.4   
4/24  
11/24   
NR 
A/Washington/897/80          
DMID Protocol 18- 0010 Version 3.0 
H1N1 Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
 29 
  
Reference  Dose 
(log 10 
TCID
50) Proportion of Subjects*  
Mean Peak Titer 
Virus Shed (log 10 
TCID 50 ± SE)  Mean Duration of 
Shedding (Days ± 
SE) Proportion of Subjects with  
Infected† Shedding 
Virus  Systemic 
Febrile 
Illness  Respiratory 
Illness  Lower 
Respiratory 
Illness‡ 
Clements et al.  (1986) 
[26] 6.0 25/27  22/27  3.8±1.6  4.3±2.0  10/27  7/27 3/27 B B/Ann Arbor/1/86  
Clements et al.  (1990) 
[37]  
7.0  
10/12   
8/12  
4±0.7   
5.4±1   
2/12  
5/12  
NR 
B/Texas/1/84  
Keitel et al.  (1990) [38]  
7.1  
6/6  
6/6  
2.2±0.7   
5.0±0.6   
NR  
3/6  
NR 
B/Yamagata/16/86  
Treanor et al.  (1993) 
[39]  
7.0  
10/10   
7/10  
2.3  
NR  
3/10  
7/10  
2/10 
Adapted from a previous publication [17]. NR = Not Reported; * Number with finding / number evaluated; † Virus shedding, serum antibody response, or both; ‡ Reported as 
“lower respiratory illness” or “cough” ; § Expressed as median (range).  
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  30 
CONFIDENTIAL  Table 4: Dose Escalation Results with A/Bethesda/MM2/H1N1 challenge strain  
Dose  Male  Female  Total  Symptoms  Viral 
Shedding  Both 
(MMID)  Four -fold Rise 
in HAI Titer  
103 TCID 50 3 2 5 2 (40%)  0 0 1 (20%)  
104 TCID 50 4 0 4 2 (50%)  0 0 0 
105 TCID 50 2 3 5 4 (80%)  1 (20%)  1 (20%)  1 (20%)  
106 TCID 50 10 9 19 17 (89%)  9 (47%)  9 (47%)  16 (84%)  
107 TCID 50 9 4 13 11 (85%)  10 (77%)  9 (69%)  11 (85%)  
Total  28 18 46 36 (78%)  20 (43%)  19 (41%)  29 (63%)  
Data are presented as N (%).  
Abbreviations: HAI, hemagglutinin inhibition; MMID, mild -to-moderate influenza disease; TCID 50, median tissue culture 
infective dose.  
2.2.2 Study Population  
The study population will be healthy subject s (male and non -pregnant, non- breastfeeding 
females) between the ages of 18 to 49 inclusive drawn from the general communities of each 
study site. They must be non-habitual smokers, including non-habitual smokers  of marijuana or 
e-cigarettes. Subjects  must not have medical conditions at high risk for severe complications of 
influenza virus infection, as defined by the US Centers for Disease Control and Prevention 
(CDC) (Appendix C ). Up to 80 healthy subjects will undergo A/Bethesda/MM2/H1N1 virus CHI 
and their clinical manifestations, viral shedding , and immunological responses will be 
characterized .  
 Pote ntial Risks and Benefits  
2.3.1 Common Symptoms of Influenza Illness  
• Common signs or symptoms of influenza illness  include:  
• Body aches or pains  
• Chest congestion  
• Chest tightness  
• Chills  
• Congested or stuffy nose  
• Coughing  
• Diarrhea 
• Difficulty swallowing  
• Eyes sensitive to light 
• Fatigue  
• Felt dizzy  
• Fever  
• Head congestion  
• Headache  
• Lack of appetite  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  31 
CONFIDENTIAL  • Nausea  
• Runny or dripping nose  
• Scratchy or itchy throat  
• Shivering 
• Sinus pressure  
• Sleeping more than usual  
• Sneezing  
• Sore or painful eyes  
• Sore or painful throat  
• Stomach ache  
• Sweating  
• Teary or watery eyes  
2.3.2 Potential Risks  
Complications or severe signs or symptoms of influenza illness , which are unlikely to occur in 
healthy subject s who participate in this study, include:  
• Pneumonia  
• Dehydration  
• Difficult breathing  
• Severe bronchitis  
• Myocarditis  
• Myocardial infarction  
• Pericarditis  
• Guillain Barr é Syndrome/ Bell’s Palsy  
• Transverse myelitis  
• Encephalitis  
• Sinus infections  
• Ear infections  
• Worsening of chronic health conditions  
• Admission to an intensive care unit (ICU)  
• Hypoxemia/respiratory failure  
• Arrhythmia/cardiac arrest  
• Death  
There may be other risks, discomforts, or side effects that are unknown at this time.  
Risks of Nasal Lavage  or Nasopharyngeal Swabs  
Obtaining a nasal lavage fluid  or a nasopharyngeal swab can cause discomfort in the nares, a gag 
reflex, epistaxis, watery eyes, or coughing at the time of collection.  
Risks of Blood Draw  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  32 
CONFIDENTIAL  Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and 
managed by having the subject lie down. Bruising at the blood draw site may occur but  can be 
prevented or lessened by applying pressure to the draw site for several minutes. Drawing blood 
may also cause infection. The use of sterile technique will make infection at the site where blood 
will be drawn extremely unlikely. Risks for blood drawn may include anemia, however the risk is low since the total amount drawn over the entire study period is about the same as a liter of 
blood ( i.e. 525 mL). The blood volumes anticipated for specimen collection are listed in 
Appendix B .  
Risks of Chest Radiograph (CXR)  
According to the United Nations Scientific Committee on the Effects of Atomic Radiation, a 
single posterior -anterior chest radiograph (CXR) exposes the subjects  to about 0.05 mSv, which 
is about the radiation dose people are exposed to naturally over the course of 10 days. Subjects  in 
our study will have one CXR at screening (Days -30 to -3), and if deemed medically necessary as 
follow -up of an Adverse Event. Female subjects  will a serum pregnancy test, and an additional  
urine pregnancy test  if more than 7 days have passed since the serum test,  before CXR.  
Risks of Electrocardiogram (ECG)  
The electrodes of an electrocardiogram (ECG) may feel cold when applied; in rare cases, a rash or skin irritation develops where the patches are placed. This type of irritation usually resolves 
by itself, but topical medication is occasionally required. Subjects  in our study will have one 
ECG at screening (Days -30 to -3), a repeat ECG at study Day 6, and additional ECGs if deemed 
medically necessary.  
Risks of Xofluza ( Baloxavir Marboxil) Antiviral  
Adverse events reported in at least 1% of adult and adoles cent subjects treated with baloxavir 
marboxil included diarrhea (3%), bronchitis (2%), nasopharyngitis (1%), headache (1%) and 
nausea (1%)  [40]. Influenza A viruses with treatment -emergent amino acid substitutions at 
positions associated with reduced susceptibility to baloxavir marboxil in cell culture have been 
observed in clinical studies. It is theoretically possible that baloxavir marboxil treatment can 
cause treatment -emergent baloxavir marboxil resistant viruses. The overall incidence of 
treatment -emergent amino acid substitutions associated with reduce d susceptibility to baloxavir 
marboxil in two prior clinical trials was 2.7% (5/182) and 11% (39/370)  [40]. 
Risks of Delaying Influenza Vaccin ation Until 60 Days Post -challenge  
In the US,  routine annual i nfluenza vaccin ation is recommended for all persons , with an 
emphasis placed on vaccin ation of high-risk groups and their caregivers . In this study, subjects 
are asked to delay 2019- 2020 influenza season vaccin ation through 60 days post -challenge . If the 
influenza season begins before this time, the subjec t is at risk of developing influenza illness.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  33 
CONFIDENTIAL  Symptoms of influenza are described in 2.3.1  and the potential risks of influenza are described 
above in this Section .  
Risks of Genetic Testing  
Genetic data and health information may be stored and shared with other researchers  through a 
controlled -access repository, such as dbGaP . There may be a risk that information resulting from 
research genetic testing could be misused for discriminatory purposes. However, state and 
federal laws provide some protections against genetic discrimination. Researchers who will have 
access to genetic information but will take measures to maintain the confidentiality of the 
information.  HLA genetic testing will be performed for research purposes only and will not be 
performed by a CLIA certified laboratory.  Therefore, the results of HLA testing will not be 
shared with subjects.   
2.3.3 Potential Benefits  
There is no direct benefit to the subjects . There is potential benefit to society and future patients 
resulting from insights gained from participation in this study.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  34 
CONFIDENTIAL  
 STUDY OBJECTIVES  AND OUTCOME MEASURES  
Refer to  Table 1 Study Objectives and Outcome Measures  
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  35 
CONFIDENTIAL  
 STUDY DESIGN  
This is a  CHI study of Influenza  A/Bethesda/MM2/H1N1  virus to assess clinical response, 
immunological response, and safety. The study population will be healthy subject s (male and 
non-pregnant, non-breastfeed ing females) between the ages of 18 to 49, inclusive. Up to 80 
subjects  will receive A/Bethesda/MM2/H1N1 virus CHI. Their clinical manifestations, viral 
shedding, and immunological responses will be characterized.  
Influenza A/Bethesda/MM2/H1N1  virus  CHI will be performed using a 2 mL dose of 
approximately 5x106 TCID 50/mL, which has been shown to induce 60% or higher rates of 
MMID  [19]. The primary objective of the study will be to evaluate the association of MMID  
post-challenge  and pre -existing virus -specific HAI titers in healthy subjects.  MMID is defined as 
the presence of both of the following, assessed through day 8:   
• Viral shedding detected by any approved positive RT-PCR  assay  from a NP swab, and 
• Any one or more of the following symptoms or signs or laboratory findings, as related to 
the study agent; Arthralgia, Chest tightness, Chills, Conjunctivitis, Nasal congestion, Sinus Congestion, Coryza, Decreased appetite, Diarrhea, Dry Cough, Dyspnea/Shor tness 
of Breath, Fatigue/Tiredness, Fever (>38.0°C), Headache, Lymphopenia (<1000 
cells/mL), Myalgia, Nausea, Oxygen Saturation Decrease by ≥3% from baseline, Productive Cough, Rhinorrhea, Sore Throat, and Sweats.  
During Study Days -30 to -3 (Screening Period), subjects will provide informed consent  to 
participate in this study. They will undergo a review of medical  history , physical examination by 
a study physician, and screening laboratory tests . During this period,  subjects will also have a 
Posterioranterior (PA) and Lateral chest X -ray (CXR), and a baseline 12-lead ECG . 
After enrollment, subjects will be admitted to an inpatient challenge unit (Day -2). Each study 
site will perform CHI on  up to 20 subjects  unless otherwise directed by DMID to meet the total 
number to be enrolled. This may be done in one or two cohorts . Backup subjects will be admitted 
into the inpatient unit to ensure sufficient number of volunteers undergo CHI, given the potential 
for drop -outs, presence of new exclusionary criteria, and/or pre-challenge evidence of viral 
respiratory infection among subjects. The number of backups will depend on site -specific 
considerations, such as anticipated drop-out rates, anticipated development of new exclusionary 
criteria, and respiratory virus circulation in the community.  A review of eligibility criteria, and 
baseline clinical assessments, safety blood tests, influenza virology, and immunology tests  will 
be performed and the subject s will have approximately a 48-hour window to decide if they 
would like to drop out of the study and leave the inpatient unit before CHI. Subjects must have 
no evidence of a respiratory viral infection  as determined by multiplex respiratory virus RT-PCR 
assay  testing prior to CHI  (posi tive results prior to CHI will exclude the subject from the 
challenge, and additional subjects may serve as replacements) . On Day -1, subjects will be 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  36 
CONFIDENTIAL  trained on the influenza patient related outcomes Flu-PRO  Survey Instrument  and Validation 
Diary [41].  
On Day 1, eligibility and clinical status will be reviewed. If criteria for proceeding with 
challenge are met, subjects  will receive A/Bethesda/MM2/H1 N1 CHI . One mL of 
A/Bethesda/MM2/H1N1 will be delivered in each nostril of a recumbent subjects per a study 
SOP. Backups will be discharged from the inpatient unit  prior to challenging other subjects  if 
they are not needed to replace ineligible subjects or subjects declining to proceed with CHI.  
After CHI, subjects will complete daily self -assessments using the Flu -PRO Survey Instrument  
[41] and Validation D iary through 14 days post -challenge  to generate a symptom severity score . 
Subject clinical status will be monitored closely. Safety labs will be performed at scheduled 
times. Subjects will undergo scheduled blood draws, nasal lavages, and nasal swab collections 
for immunology and virologic laboratory testing.  Immunologic evaluations will include 
assessment of antibody and cytokine response , T and B cell response s, and systemic 
transcriptional responses . Quantitative  and qualitative  evaluation of influenza will be done after 
CHI on Days 2 through 8. Subjects will also undergo daily  qualitative evaluations for evidence 
of influenza by multiplex respiratory virus RT -PCR assay. Subjects will remain blinded to the 
results of their respiratory virus testing until they meet discharge criteria. An ECG will be 
performed at Day 6  on all subjects , and as clinically indic ated at any other time .  
Following CHI, subjects  will remain in the inpatient unit for a minimum of seven additional days 
and will be discharged only if 1) they have  two consecutive negative influenza tests  (that are 
performed on days 7 and 8) for influenza A using a multiplex respiratory virus assay 
(BIOFIRE® FILMARRAY® or Luminex xTAG® ), AND 2)  have been afebrile (<38.0°C), have 
a room air SpO 2 ≥95 and have been clinically and hemodynamically stable for at least 48 hours. 
Discharge evaluatio n and criteria will be further described in a study SOP. In addition, subjects 
may have residual and/or resolving symptoms of influenza illness. It is expected that most 
subjects  will shed the challenge  virus for three to five days post exposure.  
If subje cts are still shedding virus on Day 8, they will remain in the challenge unit, be offered 
one dose of baloxavir marboxil (a full treatment course), and they will continue to have 
nasopharyngeal ( NP) swabs tested daily until they have two  negative influenza tests performed 
on consecutive days and meet clinical discharge criteria described above .  
Any subject who develops serious related or unrelated signs or symptoms during inpatient stay  
will receive appropriate and as clinically necessary escalation of care (e.g., cardiologist consultation for  cardiac symptoms  or transfer for evaluation at the Emergency Department). Any 
subjects  who experience complications or sequelae due to CHI will be followed until resolution 
and/or stable , and they will be referred for appropriate specialized care as clinically necessary. 
SOPs will be utilized  to standardize evaluation and care for select known complications of 
influenza virus infection. All subjects  will be followed for approximately 90 days post -challenge. 
Additional follow -up will be performed at in-person Visits 9 (Day 15), 10 (Day 29) and 11 (Day 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  37 
CONFIDENTIAL  61). Subjects will also undergo scheduled blood draws and, nasal lavages for immunology and 
virologic laboratory testing during this follow up period. A final follow -up by telephone will 
occur on Visit 12 ( Day 91). 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  38 
CONFIDENTIAL  
 STUDY INTERVENTION/INVESTIGATIONAL 
PRODUCT  
 Study Product Description  
5.1.1 Formulation, Packaging, and Labeling  
The study agent in this protocol is a biologic (live virus) and requires special storage and 
handling.  The A/Bethesda/MM2/H1N1 human challenge virus was manufactured in certified 
Vero cells under Good Manufacturing Practice (GMP) conditions by Charles River Laboratories in Malvern, PA from a reverse-genetics (RG) derived virus seed stock produced by Dr. Matthew 
Memoli and his laboratory team in the Viral Pathogenesis and Evolution Section  of the 
Laboratory of Infectious Diseases (NIAID). The rescued  RG derived virus was passaged six 
times in certified Vero cells to produce the seed virus.   
The final product was vialed at approximately  5 X 10
6 TCID 50/mL of Influenza A Human 
Challenge  Virus  (H1N1)  in 1X SPG (sucrose, 0.218 M; KH 2PO 4, 0.0038 M; K 2HPO 4, 0.0072 M; 
L-glutamic acid, 0.0054 M).  Each vial has a fill volume of 1.1 mL. The filled vials were  snap 
frozen in a dry ice -ethanol bath and stored at -80°C ± 15°C.   
Each vial will be individually labeled with the product  name, description, and caution statement. 
The label was affixed to 2  mL cryogenic vials prior to final fill with A/Bethesda/MM2/H1N1  
Virus [Charles River Laboratories] (Lot #MM001).  
The Challenge  virus is on an on-going stability and potency program and the most recent 
potency assessment performed in June 2019 is 5x106 TCID 50/mL. CHI will be performed using a 
2 mL dose of approximately 5x106 TCID 50/mL virus and will be administered intranasally. 
Intranasal CHI will be carried out using the MAD Nasal sprayer device (Wolfe -Tory Medical, 
Salt Lake City, Utah) attached to a 1  mL Luer lock  syringe.  One mL of virus will be delivered in 
each nostril of a recumbent subject . 
5.1.2 Product Storage and Stability  
Influenza A/Bethesda/MM2/H1N1)  
The human challenge virus will be stored at -80°C ± 15°C  in single -use vials.  Additional details 
of product storage and stability can be found in the MOP . Preparation and dosing of the agent 
must take place within three  hours of  removing the virus from the freezer.  The MAD Nasal 
sprayer device (Wolfe -Tory Medical, Salt Lake City, Utah) will be stored at room temperature  
(15 -30°C) . 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  39 
CONFIDENTIAL  
 Acquisition/Distr ibution  
Influenza A/Bethesda/MM2/H1N1 
The human challenge virus will be stored and distributed by the DMID  Clinical Material 
Services ( CMS) to designated VTEU sites.  The study agent will be handled by study personnel 
and administered only in the inpatient unit. The MAD Nasal sprayer device (Wolfe-Tory 
Medical, Salt Lake City, Utah) will be obtained and distributed by the DMID -Clinical Material 
Services (CMS) to designa ted VTEU sites.  
 Dosage /Regimen , Preparation , Dispensing  and Administration of 
Study Intervention/Investigational Product  
Influenza A/Bethesda/MM2/H1N1  
All steps in preparing the syringes and attaching MAD nasal atomizer to each syringe should be 
performed with careful sterile technique in a biosafety cabinet BSL Level 2 laboratory.  
CHI will be performed using a 2 mL dose  of approximately 5x106 TCID 50/mL virus and will be 
administered intranasally. Intranasal CHI will be carried out using the MAD Nasal sprayer 
device (Wolfe-Tory Medical, Salt Lake City, Utah) attached to a 1  mL syringe.  Two vials will be 
needed per subject. The time that the 2 vials are withdrawn from the freezer will be documented 
in the Accountability Log. Once thawed 1.0  mL of virus will be drawn from each of vial  and 
kept on wet ice until administered . Prior to administration the syringe will be attached to the 
MAD nasal atomizer. The total time from freezer to administration will not exceed 3 hours. One 
mL of virus will be delivered in each nostril of a recumbent participant. CHI will be performed 
according to the study MOP. 
The challenge virus is nearly identical to circulating influenza A H1N1pdm09 viruses. This virus 
is susceptible to FDA -approved neuraminidase inhibitors oseltamivir and zanamivir and 
sequencing does not indicate any mutations that confer baloxavir marboxil resistance [42, 43] . 
The 2009 H1N1pdm viruses are resistant to the adamantane class of influenza antivirals [43]. 
Full genomic sequencing was performed on the 2009 H1N1 Challenge  Virus (Lot MM#0 01). A 
total of 4 nucleic acid changes post manufacturing were observed, 1 each in HA, PA, and NA , as 
well as one synonymous change . The three  nonsynonymous changes were found as the dominant 
base in a double peak during sequencing along with the original  wild-type ( wt) nucleotide. There 
is no indication that the 2009 H1N1 Challenge  Virus  would behave any differently in humans 
than the wt influenza A/California/04/2009 (H1N1 ) virus, based on the in vitro and in vivo data.  
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  40 
CONFIDENTIAL  Table 5:  Study Intervention Regimen  
Product Name  Dose  Route  Frequency of 
Administration  
A/Bethesda/MM2/H1N1  2 mL of 
approximately 
5x106 
TCID 50/mL Intranasal  Challenge  virus will be 
administered once on Day 1  
TCID 50, median tissue culture infective dose  
 Pre-determined Modification of Study Intervention/Investigational 
Product for a n Individual  Subject  
Not applicable. DMID will not permit modification of study product dose or regimen.  
 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
Influenza A/Bethesda/MM2/H1N1 will be stored and shipped from the DMID contract or CMS  to 
the Clinical Sites.  Once received, Influenza A/Bethesda/MM2/H1N1 will be stored in and 
dispensed by the Investigational Pharmacy.   
After receipt of the study products, the site principal investigator is responsible for study product 
distribution and disposition and has ultimate responsibility for study product accountability. The 
site principal investigator may delegate to the participating site’s research pharmacist responsibility for study product accountability. The participating site’s research phar macist will 
be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study product(s). All study product(s), whether administered or not, must  be documented on the appropriate study 
product accountability record or dispensing log. The sponsor’s monitoring staff will verify the participating site’s study product accountability records and dispensing logs per the site 
monitoring plan.  
Used and unused of study products will be retained until monitored and released for disposition, as applicable. This can occur on an ongoing basis for used study products.  
Used study products may be destroyed in accordance with site -specific SOPs following each 
monit oring visit where study product accountability is monitored, and resolution of any 
discrepancies.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  41 
CONFIDENTIAL  Final disposition of the unused study products will be determined by DMID and communicated 
to the participating sites by the DMID Clinical Project Manager.  
The FDA requires accounting for the disposition of all investigational products.  The Investigator 
is responsible for ensuring that a current record of product disposition is maintained,  and product 
is dispensed only at an official study site by authorized personnel as required by applicable regulations and guidelines.  Records of product disposition, as required by federal law, consist of 
the date received, date administered, quantity administered, and the subject number to whom the drug was administered.  
The Investigational Pharmacist will be responsible for maintaining accurate records of the 
shipment and dispensing of the investigational product.  The pharmacy records must be available 
for inspection by the DMID monitoring contractors and  is subject to inspe ction by a regulatory 
agency ( e.g., FDA) or the Sponsor at any time.  An assigned Study Monitor will review the 
pharmacy records.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  42 
CONFIDENTIAL  
 SELECTION OF SUBJECTS AND STUDY 
ENROLLMENT AND WITHDRAWAL  
Subject Inclusion and Exclusion Criteria must be confirmed by a study clinician licensed to make 
medical diagnoses.  No exemptions are granted on Subject Inclusion/Exclusion Criteria in DMID -
sponsored studies. Questions about eligibility will be directed toward the DMID Medical Officer.  
 Eligibility Criteria  
6.1.1 Subject Incl usion Criteria  
Subjects eligible to participate in this study must meet all of the following inclusion criteria: 
1. Provide written informed consent prior to initiation of any study procedure.  
2. Are able to understand and comply with planned study procedures and be available for all 
study visits.  
3. Agree to remain an inpatient for at least seven days after challenge, AND until they have no 
virus shedding,1 determined by qualitative RT-PCR for a minimum of two consecutive days 
post-challenge  
1For a min imum of seven days post-challenge  (Study Day 8) . 
4. Healthy2 males and non -pregnant, non-breastfeed ing females3 aged ≥18 and ≤49 years of 
age, inclusive, at enrollment.  
2Good health is defined in inclusion criteria # 10. 
3Females subjects  of childbearing potential must agree to have a serum pregnancy test at 
screening , a urine pregnancy test before CXR performed (if more than 7 days have passed 
between CXR and serum pregnancy test) , and a urine pregnancy test upon admission to the 
inpatien t unit prior to CHI, and results must be negative.  
5. Women of childbearing potential4 must agree to use  or have practiced  true abstinence5 or use 
at least 1 acceptable primary form of contraception6,7  
These criteria are applicable to females in a heterosexual relationship and child-bearing 
potential (i.e., the criteria do not apply to subjects in a same sex relationship).  
4Not of child bearing potential - post-menopausal females (defined as having a history of 
amenorrhea for at least one year) or a documented status as being surgically sterile 
(hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or Essure® placement 
with history of documented radiological confirmation test at least 90 days after the procedure).  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  43 
CONFIDENTIAL  5True abstinence is 100% of time no sexual intercourse (male’s penis enters the female’s 
vagina). (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post -ovulation 
methods] and withdrawal are not acceptable methods of contraception).  
6Acceptable forms of primary contraception include  monogamous relationship with a 
vasectomized  partner  who has been vasectomized for180 days or more prior to the subject 
receiving the influenza challenge virus, intrauterine devices, birth control pills, and 
injectable/implantable/inser table hormonal birth control products.  
7Must use at least one acceptable primary form of contraception for at least 30 days prior to 
admission and at least one acceptable primary form of contraception during the remainder 
of the study.  
6. Non-habitual smoker8 of tobacco, e -cigarettes  or marijuana .  
8Non-habitual smokers are those who smoke no more than four cigarettes, other tobacco 
products,  e-cigarettes  or marijuana in a week  for more than three  months and agree not to 
smoke  cigarettes, other tobacco  products , e-cigarettes  and/or marijuana products during 
participation in the study.  
7. No self -reported or known history of alcoholism or drug use within the last 30 days  and 
agrees to abstain from alcohol and drugs9 for at least one week before admission and 
throughout the inpatient period.  
9 including forms of marijuana not included in criterion  6 
8. Negative drug urine toxicology result on screening (i.e., amphetamines, cocaine, and opiates)  
and on admission to the challenge unit (i.e., amphetamines, cocaine, opiates , and 
cannabinoids ). 
9. Agree not to use the listed10 prescription or over -the-counter medications within 7 days prior 
to inpatient stay and through inpatient stay, u nless approved by the investigator.  
10Oseltamivir , zanamivir, peramivir, baloxavir marboxil, amantadine (generic) and 
rimantadine (Flumadine and generic), aspirin, intranasal steroids, decongestants, antihistamines, and other non-steroidal anti-inflammatory drugs (NSAIDs).  
10. In good health
11 and not have clinically significant medical, psychiatric, chronic or 
intermittent health conditions including those listed in Exclusion Criteria  (Section  6.1.2 ). 
11Good health, as determined by medical history, medication use and physical examination to 
evaluate ongoing chronic medical or psychiatric diagnoses or conditions, defined as those 
that have been present for at least 90 days, which would not affect the assessment of the 
safety of subjects or the immunogenicity of challenge . These medical diagnoses or conditions 
should be stable for the last 90 days (no hospitalizations, emergency room (ER) or urgent 
care for condition (excluding musculoskeletal conditions) and not listed in Exclusion Criteria 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  44 
CONFIDENTIAL  (Section  6.1.2 ). Subjects may be on medications only if the condition or disease is stable  and 
not deteriorat ing, if the medical intervention (such as device or medication) was not 
available during the maxim al inpatient  period of time, medications are not listed in the 
Exclusion Criteria (Section  6.1.2 .) and pose no additional risk to subject safety or assessment 
of adverse events . This also includes no change in prescription medication, dose or 
frequency as a result of new symptoms or deterioration of the medical diagnosis or condition 
in the 90 days prior to enrollment. Any prescription change that is due to change of health 
care provider, insurance company, etc., or that is done for financial reasons, as long as in 
the same class of medication, will not be considered a deviation of this inclusion criter ion. 
Any change in prescription medication due to improvement of a disease outcome (e.g., 
lowering of the dosage or frequency), as determined by the site principal  investigator (PI) or 
designated clinician licensed to make medical diagnoses and listed on Form FDA 1572, will 
not be considered a deviation of this inclusion criterion.  
11. Does not have an ongoing symptomatic condition12 for which subject has had or has ongoing 
medical investigations but ha s not yet received a diagnosis or treatment plan.   
12e.g., ongoing fatigue without a diagnosis for symptom.  
12. Vital signs as follows: pulse is 47 to 99 beats per minute, inclusive; systolic blood pressure is 
85 to 139 mmHg, inclusive;  diastolic blood pressure is 55 to 89 mmHg, inclusive;  SpO 2 
>95%; RR<18; oral temperature is less than 100.0°F.  
13. Eligibility laboratory value s (WBC, Absolute L ymphocyte Count, Hgb, PLTs, ALT and Cr) 
are within acceptable parameters . (See Table 6) 
14. Body mass index (BMI) >18.5 and <35 kg/m2 at screening.  
15. Other screening tests (ECG  and CXR) are within normal reference range or not deemed 
clinically significant by the PI  or appropriate sub-investigator13 
13Designated clinician licensed to make medical diagnoses and listed  on the Form FDA 1572  
16. Negative test for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV)  at screening 
blood draw . 
17. Negative respiratory virus panel by BIOFIRE® FILMARRAY® respiratory panel by bioMérieux or by Luminex xTAG®  on Day -2, and Day -1. 
6.1.2 Subject Exclusion Criteria  
Subjects eligible to participate in this study must not meet any of the following exclusion 
criteria:  
1. Female subject who has a positive pregnancy test on screening or admission, is breastfeed ing 
or planning to become pregnant from 30 days prior to challenge through the end of the study. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  45 
CONFIDENTIAL  2. Presence of self -reported or medically documented significant medi cal or psychiatric 
condition(s)14 
14Significant medical or psychiatric conditions include but are not limited to:  
a. Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma ) 
requiring daily medications15 currently or any treatment of respiratory disease 
exacerbations (e.g., asthma exacerbation) in the last 5 years  
15Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene 
modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.  
b. Presence of any febrile illness or symptoms suggestive of a respiratory infection 
within two weeks prior to CHI.  
c. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.  
d. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, 
encephalopathy, focal neurologic deficits, Guillain-Barre syndrome, encephalomyelitis or transverse myelitis).  
e. Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding basal cell carcinoma of the skin, which is allowed.  
f. An autoimmune disease.   
g. An immunodeficiency of any cause.  
h.  A history of diabetes.  
3. Presence of immunosuppression or any medications that may be associated with impaired 
immune responsiveness
16- 
16Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, 
allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or 
systemic corticostero ids or other similar or toxic drugs during the preceding 12-month 
period prior to screening. Low dose topical  and intranasal  steroid preparations used for a 
discrete period of time are permitted (Section  8.1). 
4. Known allergy or intolerance to treatments for influenza (including but not limited to 
oseltamivir, baloxavir marboxil , acetaminophen).  
5. Known allergy to two or more classes of antibiotics ( e.g., penicillins, cephalosporins, 
fluoroquinolones, or glycopeptides).  
6. Known allergy to excipients in the challenge virus inoculum.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  46 
CONFIDENTIAL  7. Receipt or planned receipt of any investigational drug/ investigational vaccin e/licensed 
vaccin e within 30 days prior to the  date of CHI.  
8. Prior enrollment in any influenza virus challenge study.  
9. Currently enrolled in any investigational study or intends to enroll in such a study within the 
ensuing study period.  
10. Receipt of any influenza  vaccine six months prior to challenge  or plans to receive influenza 
vaccin e within  60 days post-challenge . 
11. History of a previous severe allergic reaction of any kind with generalized urticaria, 
angioedema, or anaphylaxis.  
12. Receipt of blood or blood products during the six months prior to the planned date of challenge. 
13. History of blood donation during the two months prior to the planned date of challenge  and 
or plans to donate blood for the duration of the study.  
14. Any condition, to include medical and psychiatric conditions, that in the opinion of the Investigator, might interfere with the safety of the subject and/or study objectives.  
15. Known close contact with anyone known to have influenza 7 days prior to challenge . 
16. Acute medical condition with new prescription medicatio n use in the last 30 days.  
17. Significant abnormality altering the anatomy of the nose/nasopharynx
17 clinically significant 
nasal deviation, or nasal/sinus surgery within 180 days prior to challenge .  
17including significant nasal polyps.  
18. History in the last five years of chronic or frequent intermittent sinusitis.  
19. Recent history (180 days) of epistaxis or anatomic or neurologic abnormality impairing the 
gag reflex or contributing to aspiration.  
Table 6: Clinical Laboratory Normal Ranges  
Hematology  Normal Range  
WBC x 103/µL  3.70 -11.00  
Absolute Lymphocyte count  x103/µL   > 1.0 
Hgb g/dL (Female)  > 11.0 
Hgb g/dL (Male)  > 12.5 
Platelets cell  x103/µL EDTA  163 – 375 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  47 
CONFIDENTIAL  Platelets K/cu mm Citrate  125 – 375 
Chemistry   
ALT IU/L (Female)  < 43 
ALT IU/L (Male)  < 60 
Creatinine mg/dL  < 1.4 
 Withdrawal from the Study, Discontinuation of Study Product, or 
Study Termination  
6.2.1 Discontinuation of the Study Product  
Not applicable  
6.2.2 Subject Replacement  
Subjects who withdraw, are withdrawn from this study, or are lost to follow -up after signing the 
informed consent form (ICF) an d administration of the study product will not be replaced. 
Subjects who withdraw, are withdrawn from this study, or are lost to follow -up after signing the 
ICF but before administration of the study product may be replaced.  
6.2.3 Study Termination  
If the stud y is prematurely terminated by the Sponsor, any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure 
appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the termination to the IRB/IEC.  
6.2.4 Withdrawal during  the Inpatient Period   
Subjects may withdraw voluntarily from participation in the study at any time.  Subjects may also 
withdraw voluntarily from receiving the study intervention for any reason.  
Subjects will have approximately a 48-hour window to decide if they would like to drop out of the study and leave the inpatient unit before CHI. The investigator should be explicit regarding 
study follow -up ( e.g., safety follow -up) that might be carried out once the subject undergoes CHI 
but decides to leave inpatient unit before discharge criteria are met.  
Subjects will be strongly discouraged from withdrawing from the study post -challenge. Any 
subjects who withdraws from the study post -challenge but prior to meeting the discharge criteria 
outlined will be asked to sign a document stating that they are aware of the potential risks of developing influenza complications, they are aware of the risks of transmitting influenza virus to 
high-risk populations ( Appendix C ), and that they will stay sequestered in their homes and avoid 
contact with others until they have two negative test s for influenza virus by qualitative RT-PCR. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  48 
CONFIDENTIAL  The PI , co-investigator or  study team will counsel the subject on infection control practices to 
minimize any community transmission. Subjects without two consecutive days of negative tests 
for influenza virus by qualitative RT-PCR will be given one dose of baloxavir marboxil  at the 
time of premature withdrawal from the study. For the purposes of safety and serological testing, the subject will also be asked to come for all follow -up visits. If the subject leaves the inpatient 
unit prior to Day 8, whether or not they are continuing to shed virus, the subject will be 
encouraged to return for follow -up visits per outpatient schedule (i.e., Visits 9, 10, 11 and phone 
call at Visit 12). If the subject does not return for scheduled follow -up visits, extensive effort 
(i.e., at least three documented contact attempts via phone calls, e-mails, text message, or private 
social media communication, etc., as voluntarily provided by the subject and based on local IRB 
recommendations, made on at least 3 separate days and followed by a certified let ter if 
unsuccessful) will be made to locate the subject and reiterate that follow -up visits are strongly 
encouraged for safety reasons. These efforts will be documented in the subjects’ records. See the 
MOP for Subject Contact Information.  The investigator  will inform the subject that already 
collected data will be retained and analyzed even if the subject withdraws from this study.  If a 
subject withdraws or is withdrawn prior to completion of the study, the reason for this decision 
must be recorded in the case report forms (CRFs).  
6.2.5 Withdrawal during the Follow -up Period  
Subjects may withdraw voluntarily from participation in the study at any time.  Subjects will be 
strongly discouraged from withdrawing from the study during the follow -up period . For the 
purposes of safety and serological testing, the subject will also be asked to come for all follow -
up visits. The subject will be encouraged to return for follow -up visits per outpatient schedule 
(i.e., Visits 9, 10, 11 and phone call at Visit 12). The investigator will inform the subject that 
already collected data will be retained and analyzed even if the subject withdraws from this 
study.  As discussed in 5.2.6, if  a subject withdraws or is withdrawn prior to completion of the 
study, the reason for this decision must be recorded in the case report forms (CRFs).  
6.2.6 Reasons for withdrawal might include, but are not limited to the following:  
• Subject no longer meets eligibility criteria (prior to challenge)  
• Subject meets individual halting criteria ( Section  9.6.1 ) 
• Subject becomes noncompliant  
• Medical disease or condition, or new clinical finding(s) for which continued participation, in the opinion of the investigator might compromise the safety of the subject, interfere with the subject's successful completion of this study, or interfere with 
the evaluation of responses  
• Subject lost to follow -up 
• Subject becomes pregnant, if applicable  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  49 
CONFIDENTIAL  • Determined by a physician’s discretion to require additional therapy not indicated in the 
protocol to ensure subject’s health and well -being (or treatment failure, if applicable)  
• If the subject consents, every attempt will be made to follow all adverse events (AEs) 
through resolution or stabilization.  
• Clinical samples/data may be used for study analyses despite withdrawing early from the study.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  50 
CONFIDENTIAL  
 STUDY PROCEDURES  
 Screening  Period  
7.1.1 Study Visit 00A (Day -30 to -3) 
The screening sequence is designed to minimize subjects s tudy visits and needle sticks, while 
identifying exclusionary criteria early and before more time -intensive and costly tests are 
performed and before the inpatient challenge stay begins. The screening may occur over more 
than one day and may encompass more  than one visit.  
• Subjects will be provided with a description of the study (purpose and study procedures) 
and asked to read and sign the ICF.  The ICF will be signed prior to performing any study 
procedure.  
• Demographic information will be obtained by interview of subjects.  
• Eligibility criteria will be reviewed with subjects.  
• Complete medical history will be obtained . 
• All concomitant medications taken within 90 days prior to signing the ICF will be 
reviewed with subjects to determine stability of chroni c diseases and eligibility. 
Medications reported in the eCRF are limited to those taken within 30 days prior to CHI.  
• Documentation of receipt of 2018/2019 influenza vaccine  
• Subject receipt of non-seasonal influenza vaccine, including those that are experi mental,  
product type  (inactivated or live attenuated), vaccine virus strains  (e.g., A/H3 N2v, A/H5, 
A/H7, A/H9 , etc.) and approximate date of vaccination will be recorded on the 
appropriate DCF, if known.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature) will be obtained .  
• Physical exam  
• A serum pregnancy test will be performed on all female subject  of childbearing potential 
and result must be negative . 
• Height and weight will be collected . 
• Blood for safety labs ( approximately 15 mL), including HIV, hepatitis B,  and hepatitis C 
testing, and testing for white blood cells (WBCs), absolute lymphocyte count, 
hemoglobin, platelets, alanine transaminase (ALT)  and creatinine (Cr) will be sent to a 
central lab for evaluation and uploaded and entered into Advantage eClinicalSM. These 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  51 
CONFIDENTIAL  values must be confirmed to meet the eligibility criteria as outlined in the Inclusion 
Criteria ( Section  5.1.1 ) prior to admission to the inpatient unit.  
• Urine toxicology test (amphetamines, cocaine, and opiates, )  will be performed  at the 
Central Lab . 
• 12-lead ECG will be performed and confirmed to be within normal limits  or not clinically 
significant as determined  by the PI or designated clinician licensed to make medical 
diagnoses and listed on Form FDA 1572 prior to admission to the inpatient unit. 
• CXR will be performed  and confirmed to be within normal limits or not clinically 
significant as determined by the PI  or designated clinician licensed to make medical 
diagnoses and listed on Form FDA 1572 prior to admission to the inpatient unit. Among 
female subjects of childbearing potentia l, a repeat urine pregnancy test will be performed 
locally if >7 days have passed since the negative serum pregnancy test was drawn.  The 
result of the urine pregnancy test must be negative before the CXR is performed. 
• Eligibility criteria will be reviewed with subjects in the wee k prior to admission to the 
inpatient unit to confirm no new exclusion criteria have been met since the review at 
initial enrollment. 
 Inpatient Period  
7.2.1 Study Visit 00B (Day -2) 
• The subjects  will be admitted to inpatient unit.  
• Eligibility criteria will be reviewed with subjects.  
• Subject’s  willingness to participate will be reconfirmed and documented in the study 
records prior to performing any further study procedures. The subject  will have 
approximately a 48-hour window to decide if they would like to drop out of the study and 
leave the inpatient unit before virus is administered.  
• Vital signs (including SpO 2, HR, RR , BP and oral temperature ) will be obtained.  
• Weight will be collected for cal culation of BMI (with height collected on Day -30 to -3).  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated . 
• Medical history will be obtained. 
• All concomitant medications will be reviewed with subjects for accuracy and 
completeness. Any new concomitant medications taken since the screening visit will be 
reviewed with subjects and assessed for continued eligibility .  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  52 
CONFIDENTIAL  • A urine pregnancy test will be performed  locally  on all female subject s of childbearing 
potential and a positive result will exclude the subject from receipt of study product.   
• Blood ( approximately 20 mL) for antibody and cytokine assays  
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
phenotyping ( cryopreserved  PBMC ) 
• Blood ( approximately 48 mL) for T and B immunology (cryopreserved PMBC)  
• Blood ( approximately 2.5 mL) for transcriptomics  
• A quali tative  multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be 
performed to assure that no subject has a respiratory viral infection (positive resul ts will 
exclude the subject from enrollment, and additional subjects may be admitted as 
replacements if any subjects are excluded prior to challenge). .  
• NLF  will be collected for baseline immunology assays . 
• Urine toxicology test ( amphetamines, cocaine, opi ates, and cannabinoids)  will be 
performed locally.  Results must be negative for subject to continue participation in the 
study.  
7.2.2 Study Visit 00C (Day -1) 
• The subjects will remain in the inpatient unit.  
• Eligibility criteria will be reviewed with subjects.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature) will be obtained.  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be performed; additional clinical evaluation will be performed if clinically indicated.  
• Any new concomitant medications taken since the screening visit will be reviewed with 
subjects and assessed for continued eligibility.  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or  Luminex xTAG®) will be 
performed to assure that no subject has a respiratory viral infection (positive results will 
exclude the subject from enrollment, and additional subjects may be admitted as 
replacements if any subjects are excluded prior to challenge). Quantitative RT-PCR and 
culture for influenza will be performed on the same NP swab specimen.   
• NLF will be collected for baseline immunology assays if not collected at Day -2. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  53 
CONFIDENTIAL  • Subjects will be trained on Flu-PRO Survey Instrument  and Validation D iary. 
7.2.3 Study Visit 01 (Day 1)  Before Challenge  
• Subjects will remain in the inpatient unit.  
• Eligibility criteria will be reviewed with subjects . 
• Informed consent will be reviewed with subjects . 
• Baseline local and systemic symptoms will be assessed using daily Flu-PRO Survey 
Instrument  and Validation Diary  prior to challenge. All subjects will perform self -
assessment using the Flu-PRO Survey Instrument  Validation Diary  daily  during the 
inpatient stay  to generate a symptom severity.  
• Vital signs (including SpO 2*, HR, RR, and BP and oral temperature) will be obtained.  
(*For data analysis, this measurement of SpO 2 will be considered baseline.)   
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• Any new concomitant medications taken since the screening visit will be reviewed with 
subjects and assessed for continued eligibil ity. 
• Medical history will be obtained.  
• Blood ( approximately 2.5 mL) for transcriptomics . 
• Subjects will receive study influenza challenge virus . The challenge virus 
(A/Bethesda/MM2/H1N1 ) will be administered intranasally at a dose of  2 mL of 
approximately 5x106 TCID 50. Intranasal challenge will be carried out using the MAD 
Nasal sprayer device (Wolfe-Tory Medical, Salt Lake City, Utah) attached to a 1  mL 
syringe.  One mL of virus will be delivered in each nostril of a recumbent subject . 
7.2.4 Study Visit 01 (Day 1) Post-challenge  
• Subjects will remain in the inpatient unit.  
• Post-challenge  vital signs (including SpO 2, HR, RR, BP and oral temperature will be 
obtained approximately within each 8-hour period, or three times per day while subject is awake, and as clinically indicated).  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary at approximately 5 PM  (see MOP for details)  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams ) will be 
performed; additional clinical evaluation will be performed if clinically indicated . 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  54 
CONFIDENTIAL  • All AEs and SAEs, will be recorded on the appropriate DCF.  
7.2.5 Study Visit 02 (Day 2)  
• Subjects  will remain in the inpatient unit. 
• Vital signs (including SpO 2, HR, RR, BP and oral t emperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as clinically indicated).  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary  at approximately 5 PM  (see MOP for details)  
• All concomitant medication will be reviewed.  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be performed.  
• NLF will be collected for immunology assays . 
• Blood for safety labs ( approximately 10 mL), including white blood cells (WBCs), 
absolute lymphocyte count, hemoglobin, platelets, and alanine transaminase (ALT), 
creatinine (Cr) will be sent to a central lab for evaluation and uploaded and entered into 
Advantage eClinical
SM.  
• Blood ( approximately  5 mL) for cytokine assays  
• Blood ( approximately 2.5 mL) for transcriptomics  
• All AEs and SAEs, will be recorded on the appropriate DCF.  
7.2.6 Study Visit 03 (Day 3)  
• Subjects  will remain in inpatient unit. 
• All concomitant medication will be reviewed.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as clinically indicated).  
• All subjects will perform self -assessment using the Flu-PRO Survey  Instrument and 
Validation Diary at approximately 5 PM  (see MOP for details)  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  55 
CONFIDENTIAL  • Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• A qualitative mu ltiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be 
performed.  
• All AEs and SAEs will be recorded on the appropriate DCF.  
7.2.7 Study Visit 04 (Day 4)  
• Subjects  will remain in inpatient unit.  
• All concomitant medication will be reviewed.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as clinically indicated).  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary at approximately 5 PM  (see MOP for details)  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• Blood for safety labs ( approximately 10 mL), including white blood cells (WBCs), 
absolute lymphocyte count, hemoglobin, platelets, and alanine transaminase (ALT), creatinine (Cr) will be sent to a central lab for evaluation and uploaded and entered into 
Advantage eClinical
SM.  
• Blood ( approximately 5 mL) for cy tokine assays  
• From at least a subset of participants: Blood ( approximately 15 mL) for ASC (fresh 
PBMC) 
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
cell phenotyping ( cryopreserved PBMC ) 
• Blood ( approximately 32 mL) for T and B cell immunology (cryopreserved PMBC)  
• Blood ( approximately 2.5 mL) for transcriptomics  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG® ) will be 
performed.  
• NLF will be collected for immunology assays.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  56 
CONFIDENTIAL  • All AEs and SAEs will be recorded on the appropriate DCF.  
7.2.8 Study Visit 05 (Day 5)  
• Subjects  will remain in inpatient unit.  
• All concomitant medication will be reviewed.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as clinically indicated).  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary at approximately 5 PM  (see MOP for details)  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• A qualitative multiple x respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be 
performed.  
• All AEs and SAEs will be recorded on the appropriate DCF.  
7.2.9 Study Visit 06 (Day 6)  
• Subjects  will remain in inpatient unit.  
• All concomitant medication will be reviewed.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as clinically indicated).  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary at approximately 5 PM  (see MOP for details)  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; a dditional clinical evaluation will be performed if clinically indicated.  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be 
performed.  
• NLF will be collected fo r immunology assays.  
• Blood ( approximately 5 mL) for cytokine assays  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  57 
CONFIDENTIAL  • From at least a subset of participants: Blood ( approximately 15 mL) for ASC (fresh 
PBMC ) 
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
phenotyping ( cryopreserved  PBMC ) 
• Blood ( approximately 32 mL) for T and B immunology (cryopreserved PMBC)  
• ECG will be performed . 
• All AEs and SAEs will be recorded on the appropriate DCF.  
7.2.10  Study Visit 07 (Day 7) 
• Subjects  will remain in inpatient unit.  
• All concomitant medication will be reviewed.  
• Vital signs (including SpO 2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as clinically indicated).  
• All subjects will p erform self-assessment using the Flu-PRO Survey Instrument and 
Validation Diary at approximately 5 PM  (see MOP for details)  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be performed; additional clinical evaluation will be performed if clinically indicated.  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be 
performed.  
• All AEs and SAEs, will be recorded on the appropriate DCF.  
7.2.11  Study Visit 08 (Day 8)  
• Subjects begin the day in the inpatient unit  and will remain if discharge criteria are not 
met. 
• Vital signs (including SpO
2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, and as clinically indicated).  
• All concomitant medication will be reviewed.  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary. On this day, subjects may complete the  self-assessment earlier than 
previous days if they are being discharged to home.  New or changes in symptoms 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  58 
CONFIDENTIAL  between the time of self -assessment on this day and 5 PM (the usual time for self-
assessment)  will be captured in the Flu-PRO Survey Instrument and Validation Diary on 
Day 9 post -challenge  (see MOP for details) . 
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®) will be 
performed.  
• NLF will be collected for immunology assays.  
• Blood for safety labs ( approximately 10 mL), including white blood cells (WBCs), 
absolute lymphocyte count, hemoglobin, platelets, and alanine transaminase (ALT), 
creatinine (Cr) will be sent to a central lab for evaluation and uploaded and entered into 
Advantage eClinicalSM.  
• Blood ( approximately 20 mL) for antibody and cytokine assays  
• From at least a subset of participants: Blood ( approximately 15 mL) for ASC (fresh 
PBMC ) 
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
phenotyping ( cryopreserved  PBMC ) 
• Blood ( approximately 32 mL) for T and B immunology (cryopreserved PMBC)  
• Blood ( approximately 2.5 mL) for transcriptomics  
• Subjects  will be discharged once they meet all of the following discharge criteria  
(subjects  meeting discharge criteria may leave after receipt of qualitative RT-PCR results 
for the day) :  
o Have t wo consecutive qualitative RT-PCR tests on  NP swabs (that are performed on 
Day 7 or thereafter on consecutive days) that are negative for influenza A using a 
multiplex respiratory virus assay (BIOFIRE® FILMARRAY® respiratory panel by 
bioMérieux or Luminex xTAG® ).  
o Are afebrile  (< 100.4°F /38.0°C ). 
o SpO 2≥95% on room air  
o Show no moderate or severe influenza signs or symptoms  by clinical evaluation . 
o Are clinically and hemodynamically stable for at least 48 hours  (per the evaluation of 
the study physician) . 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  59 
CONFIDENTIAL  • A single dose of baloxavir marboxil will be offered to all subjects  that have not had two 
consecutive qualitative RT-PCR t ests negative for influenza  A. 
• All AEs and SAEs, will be recorded on the appropriate DCF.  
7.2.11.1  Unscheduled  Inpatient Days After Day 8  
• Subjects who are still shedding on Day 8 will remain in the inpatient unit and will 
continue to be tested until they have qualitative NP swabs that are negative for influenza 
A on two consecutive days   
• Vital signs (including SpO 2, HR, RR, BP and oral temperature will be obtained 
approximately within each 8-hour period, or three times per day while subject is awake, 
and as cli nically indicated).  
• All concomitant medication will be reviewed.  
• All subjects will perform self -assessment using the Flu-PRO Survey Instrument and 
Validation Diary  once  daily at approximately 5 PM  through day 14 post challenge  (see 
MOP for details) .  
• Targe ted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• A qualitative multiplex respiratory virus assay on NP swab specimen (BIOFIRE® 
FILMARRAY® respirato ry panel by bioMérieux or Luminex xTAG®) will be 
performed.  
• Subjects will be discharged once they meet all of the following discharge criteria (subjects meeting discharge criteria may leave after receipt of qualitative RT-PCR results 
for the day):  
o Have two consecutive qualitative RT -PCR tests on NP swabs (that are performed on 
Day 7 or thereafter on consecutive days) that are negative for influenza A using a 
multiplex respiratory virus assay (BIOFIRE® FILMARRAY® respiratory panel by bioMérieux or Luminex xTAG®).  
o Are afebrile (< 100.4°F/38.0°C).  
o SpO
2 ≥95% on room air  
o Show no moderate or severe influenza signs or symptoms by clinical evaluation.  
o Are clinically and hemodynamically stable for at least 48 hours (per the evaluation of 
the study physician) . 
o All AEs and SAEs, will be recorded on the appropriate DCF.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  60 
CONFIDENTIAL  • A single dose of baloxavir marboxil will be offered to all subjects that have not  
previously received a dose and have not  had two consecutive qualitative RT-PCR tests 
negative for influenza A.  
 Follow -up Period  
7.3.1.1  Post-discharge  (Approximately Day 9 to Day 14) 
• After discharge and through Day 14 post-challenge , subjects continue to perform daily 
self-assessment using the Flu-PRO  Survey Instrument and Validation Diary at 
approximately 5 PM  through day 14 post challenge.   
7.3.1.2  Study Visit 09 (Day 15 ± 3 Days) 3Days  
• Subjects will visit the study clinic.  
• Study personnel will collect the Flu-PRO Survey Instrument and Validation Diary from 
subjects including symptoms experienced from Days 9 to 14 post challenge .  
• All concomitant medication s will be reviewed.  
• Vital signs including HR, RR , BP and oral temperature will be obtained.   
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• Blood ( approximately 5 mL) for cytokine assays  
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
phenotyping ( cryopreserved  PBMC ) 
• Blood ( approximately 40 mL) for T and B immunology (cryopreserved PMBC)  
• Blood ( approximately 2.5 mL) for transcriptomics  
• NLF  for immunology assays.  
• All AEs and SAEs will be recorded on the appropriate DCF.  
7.3.1.3  Study Visit 10 (Day 29 ± 3 Days ) 
• Subjects will visit the study clinic.  
• All concomitant medication will be reviewed.  
• Vital signs including HR, RR, BP and oral temperature will be obtained.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  61 
CONFIDENTIAL  • Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• Blood ( approximately 20 mL) for antibody assays  
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
phenotyping ( cryopreserved  PBMC ) 
• Blood ( approximately 40mL ) for T and B immunology (cryopreserved PMBC) 
• NLF for immunology assays.  
• All unsolicited AEs  and SAEs will be recorded on the appropriate DCF.  
7.3.1.4  Study Visit 11  (Day 61 ± 5 Days ) 
• Subjects will visit the study clinic.  
• All concomitant medication will be reviewed.  
• Vital signs including HR, RR, BP and oral temperature will be obtained.  
• Targeted physical exam (lung, heart, oral/pharyngeal, and neck exams) will be 
performed; additional clinical evaluation will be performed if clinically indicated.  
• Blood ( approximately 20 mL) for antibody assays  
• From at least a subset of participants: Blood ( approximately 8 mL) for innate, T and B 
phenotyping ( cryopreserved  PBMC ) 
• Blood (40mL ) for T and B immunology (cryopreserved PMBC)  
• NLF for immunology assays.  
• All SAEs  will be recorded on the appropriate DCF.  
7.3.2 Final Study Visit  -- Telephone Follow -up (Day 91 ± 7 Days)  
• A phone call for safety follow up will be performed.   
• All SAEs will be recorded on the appropriate DCF.  
 Early Termination Visit  
Any of the following activities may be performed  at the Early Termination Visit on subjects who 
withdraw or are withdrawn or terminated from this study.  
• All concomitant medications will be recorded on the appropriate DCF.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  62 
CONFIDENTIAL  • Subject self -assessment using the Flu -PRO Survey Instrument  and Validation Diary  will 
be reviewed (if within 14 days post -challenge).  
• Vital signs, including oral temperature, pulse, RR,  and BP  may be obtained.  
• A targeted physical examination, may be performed  
• Blood or nasal specimens for safety or research purposes  may be collected depending on 
when this visit occurs . 
• All A E/SAEs will be recorded on the appropriate DCF per Section 9. 
 Unscheduled Study Visits  
An Unscheduled Visit may occur at any time during this study. Any of the following activities 
may be performed:  
• All concomitant medications will be recorded on the a ppropriate DCF.  
• Subject self -assessment using the Flu-PRO  Survey Instrument and Validation Diary  will 
be reviewed (if within 14 days post -challenge ). 
• Vital signs, including oral temperature, pulse, RR, and BP  may be obtained if indicated.  
• A targeted physical examination, may be performed  
• Blood or nasal specimens for safety or research purposes may be collected depending on 
when this visit occurs.  
• All AE/SAEs will be recorded on the appropriate DCF.  
 
 Protocol D eviations  
A protocol deviation is any noncompliance with the study protocol, GCP, or protocol -specific 
MOP requirements.  The noncompliance may be either on the part of the subject, the site PI, or 
the site personnel.  As a result of deviations, corrective actions are to be developed by the site and 
implemented promptly.  
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, Section s 4.5.1, 4.5.2, and 4.5.3  
5.1 Quality Assurance and Quality Control, Section  5.1.1  
5.20 Noncomplia nce, Section s 5.20.1, and 5.20.2.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  63 
CONFIDENTIAL  It is the responsibility of the site PI and personnel to use continuous vigilance to identify and 
report deviations within five working days of identification of the protocol deviation, or within 
five working days of the scheduled protocol -required activity.  All deviations must be promptly 
reported to DMID per the data coordinating center ( DCC) protocol deviation reporting 
procedures.  
All protocol deviations, as defined above, must be addressed in study subject data collect ion 
forms. A completed copy of the DMID Protocol Deviation Form must be maintained in the 
Regulatory File, as well as in the subject's chart.  Protocol deviations must be sent to the local 
IRB/IEC per their guidelines.  The site PI and personnel are responsible for knowing and 
adhering to their IRB requirements.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  64 
CONFIDENTIAL  
 DESCRIPTION OF CLINICAL AND LABORATORY 
EVALUATIONS  
 Clinical Evaluations  
Specifics of clinical and laboratory evaluations are in Table 11(Appendix A ). 
Screening for eligibility will occur from Days -30 to -3 to determine health status of potential 
subjects. This will include the following clinical evaluations: 
• A complete medical and medication history  
• Review of concomitant medications  
• Review of receipt of 2018/2019 influenza vaccine  
• Subject receipt of non-sea sonal influenza vaccine, including those that are experimental,  
product type, vaccine virus strains and approximate date of vaccination (Section 7.1.1 ) 
• Height and weight will be collected.  
• Vital signs (including SpO 2, RR, HR, BP, oral temperature)  
• Physical exam  
• Collection of blood for screening and baseline safety laboratory testing  
• Urine f or toxicology  
• ECG  
• Serum pregnancy test  
• Baseline PA and lateral CXR (Among women of childbearing potential, a repeat urine 
pregnancy test will be performed locally if >7 days have passed since the negative serum 
pregnancy test was drawn. The result of the urine pregnancy test must be negative before 
the CXR is performed. ) 
After enrollment, the subjects will be admitted to the inpatient unit (Day -2). Baseline 
assessments and testing will be performed after admission and the subjects will have 
approximately a 48-hour window to decide if they would like to drop out of the study and leave 
the inpatient unit before challenge  virus is administered. The following clinical evaluations will 
be performed in the 48 hours before challenge  (Days -2 and Day -1): 
• Vital signs (including SpO 2, RR, HR, BP, oral temperature)  
• Targeted physical exam  (including lung, heart, oral/pharyngeal, and neck exams)  
• Weight will be collected.  
• Complete medical and medication history  
• Review of concomitant medications  
• Urine for toxicology; results must be negative for subject to be eligible for challenge on 
day 1.  
• A urine pregnancy test will be performed locally on all female subjects of childbearing 
potential and a positive result will exclude the subject from receipt of study product.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  65 
CONFIDENTIAL  • NLF will be collected for immunology assays  on Day -2. If not  collected on Day -2, NLF  
may be collected on Day -1, but not both days .  
• NP swab will be collected for testing for qualitative evaluation of viral respiratory 
infection  
On Day 1, the challenge  virus will be administered. Baseline evaluations before CHI will include 
the following:  
• Local and systemic symptom assessment using Flu-PRO Survey Instrument and 
Validation Diary  
• Targeted physical exam (including lung, heart, oral/pharyngeal, and neck exams)  
• Complete medical and medication history  
• Review of concom itant medications  
• Vital signs including SpO 2, HR, RR, BP, oral temperature  
Subjects will be followed for a minimum of 7 days post -challenge  (through Study Day 8)  in the 
inpatient unit. The following clinical evaluations will be performed during this post -challenge , 
inpatient period:  
• Local and systemic symptom assessment using Flu-PRO Survey Instrument and 
Validation Diary  
• Targeted physical exam including height, weight, clinical evaluation (lung, heart, oral/pharyngeal, and neck exams)  
• Complete medical and medication history  
• Review of concomitant medications  
• Vital signs including SpO
2, HR, RR, BP, oral temperature  
• ECG will be performed  
• NP Swab  will be collected  for testing for qualitative evaluation of viral respiratory 
infection  
• Collection of blood for clinical laboratory tests  
 8.1.1 Research Procedures  
• Flu-PRO Survey Instrument and Validation Diary to generate a symptom severity score  
• Collection of blood for antibody and cytokine assays  
• Collection of blood for transcriptomics  
• From at least a subset of participants: Collection of blood for ASC (fresh PBMC ) 
• From at least a subset of participants: Collection of blood for innate, T and B phenotyping ( cryopreserved  PBMC ) 
• Collection of blood for T and B immunology (cryopreserved PMBC)  
• Collection of NLF for immunology assays  
• Collection of NP swab for viral shedding and viral load assessment.  
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  66 
CONFIDENTIAL  8.1.2 Assessment of Concomitant Medications/Treatments other than Study Product  
Concomitant medications will be reviewed at every study visit through the end of the study. 
Women of child bearing potential in a heterosexual relationship must agree to use true abstinence 
or use  at least one acceptable primary form of contraception through the end of the study.  
Receipt of any influenza vaccine during the 2018/2019 influenza vaccine season regardless of 
the date of receipt) will be documented.  Subject receipt of non-seasonal influenza vaccine, 
including those that are experimental,  product type, vaccine virus strains and approximate date of 
vaccination ( Section 7.1.1 ) 
The following prescription or over -the-counter medications cannot be used within 7 days  prior to 
admission to the inpatient unit and through the inpatient stay, unless approved by the 
investigator : oseltamivir, zanamivir, peramivir, baloxavir marboxil, amantadine (generic) and 
rimantadine (Flumadine and generic), aspirin, intranasal steroids, decongestants, antihistamines, 
and other non-steroidal anti-inflammatory drugs (NSAIDs).  
Subjects who use asthma medications including inhaled, oral, or IV corticosteroids, leukotriene 
modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics, will be 
excluded from the study.  
Any medications that may be associated with impaired immune responsiveness including, but 
not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections,  
immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs cannot be used during the preceding 12-month period prior to 
screening. Low dose topical  and intranasal  steroid preparations used for a discrete period of time 
are permitted.  
Subjects should not have received any investigational drug/investigational vaccine/licensed 
vaccin e within 30 days prior to the planned date of CHI.  
Subjects should not have received influenza vaccin e six months prior to challenge  and must not 
plan to receive an influenza vaccin e 60 days post challenge. 
Subjects should not have received blood or blood products during the six months prior to the 
planned date of CHI. 
8.1.3 Assessment of Subject Compliance with Study Intervention/Investigational 
Product/Investigational Device  
Subjects will be directly observed at the time of dosing by a member of the clinical research 
team who is licensed to administer the study product. Administration will be documented and 
entered i nto the eCRF.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  67 
CONFIDENTIAL  8.1.4 Non-Research Standard of Care  
Baloxavir marboxil (Xofluza) may be given to each subject  who has not had two conse cutive 
days of negative qualitative RT-PCR tests for influenza virus  on Study Day 8. Baloxavir 
marboxil is a polymerase acidic en donuclease inhibitor indicated for the treatment of acute 
uncomplicated influenza in patients 12 years of age and older [40]. Baloxavir marboxil is 
licensed as a single-dose drug.  
8.1.5 Non-Research Standard of Care  
Subjects who continue to shed virus beyond Day 8 will undergo routine daily evaluations as 
described in Section s 6 and 7. If the subject is considered by the study physician to be clinically 
well, no additional changes to study procedures will be made. The study physician may treat the 
subject  with symptom -directed, over -the-counter therapies as permitted by the study protocol. If 
the subject meets criteria for escalation of care, evaluation and treatment will be at the discretion 
of th e consulting physician.  
 Laboratory Evaluations  
8.2.1 Clinical Laboratory Evaluations  
• Hematology at Screening: white blood cells (WBCs), absolute lymphocyte count, 
hemoglobin, and platelets  (if platelets in the EDTA tube are clumped and the result is not 
available, platelets may be repeated in a citrate tube)  
• Hematology at Follow -up (at Days 2, 4, and 8): white blood cells (WBCs), absolute 
lymphocyte count, hemoglobin, and platelets  (if platelets in the EDTA tube are clumped 
and the result is not available, platelets may be repeated in a citrate tube)  
• Biochemi stry at Screening: alanine transaminase (ALT) and creatinine (Cr)  
• Biochemistry at Follow -up (at Days 2, 4, and 8):  alanine transaminase (ALT) and 
creatinine (Cr) 
• Hepatitis B and Hepatitis C, HIV at Screening.  
• A urine toxicology test (amphetamines, cocaine,  and opiates,) at screening (to be 
performed at the central laboratory) and on the day of admission to the inpatient unit 
(amphetamines, cocaine, opiates, and cannabinoids) (to be performed locally).  
• Serum HCG pregnancy test (for female subjects of childbearing potential) at screening to 
be performed at the Central Laboratory  
• Urine HCG pregnancy test (for female subjects of childbearing potential) to be done 
before the baseline CXR (if > 7 days have pa ssed since the negative serum pregnancy test 
was drawn ) and on the day of  admission to the inpatient unit, to be performed locally. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  68 
CONFIDENTIAL  • Qualitative  multiplex respiratory virus assay (BIOFIRE® FILMARRAY® respiratory 
panel by bioMérieux or Luminex xTAG®)  on NP swab  
8.2.2 Research Assays  
• HAI, MN, NAI, anti -HA-st alk antibody titers  from serum  
• sIgA titers from NLF  
• Human leukocyte antigen (HLA) class I and II alleles  from blood 
• Systemic cytokines and chemokines from serum 
• Mucosal  cytokines and chemokines from NLF  
• Transcr iptional responses from whole blood  
• Plasmablasts ( ASC ) in circulation  (from PBMC ) 
• Influenza -specific B and T cell immune responses  from PBMC s 
• Immunophenotyping of i nnate, B and T cell  subsets  in NLF   
• Quantitative RT-PCR for influenza from NP swab specimen.  
8.2.2.1  Laboratory Specimen Preparation, Handling, and Storage  
Instructions for specimen preparation, handling, and storage are included in the central (clinical) 
laboratory manual and protocol -specific MOP as appropriate.  
8.2.2.2  Laboratory Specimen Shipping  
Specimen shipment will occur at intervals during the course of this study following all applicable 
International Air Transport Association (IATA) requirements and according to the specifics for 
storage temperature and documentation as detailed in the central (clinical) laboratory manual and 
protocol -specific MOP as appropriate.  
Specimens for clinical screening and safety laboratory evaluations will be transported from the 
participating sites to the central (clinical) laboratory. Urine toxicology on the day of admission 
will be performed at the local laboratory.  
Specimens for HAI, MN , NAI and anti -HA-stalk antibody assays, transcriptomics  and 
Plasma/ PBMC -based a nd NLF -based assays will be shipped from the participating sites to 
DMID Clinical Materials Services (CMS)  and then provided by the CMS  to the appropriate 
laboratory in a blinded manner.  
Further instructions for specimen shipment are included in the central (clinical) laborat ory 
manual and protocol -specific MOP, as appropriate.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  69 
CONFIDENTIAL  
 ASSESSMENT OF SAFETY  
 Assessing and Recording Safety Parameters  
Signs, symptoms, laboratory findings that are part of MMID from the time of CHI through 14 
days post -challenge will not be considered adverse events. These signs, symptoms and laboratory 
findings (mild and moderate)  which define MMID  include the following: arthralgia, chest 
tightness, chills, conjunctivitis, nasal congestion, sinus congestion, coryza, decreased appetite, diarrhea, cough, dyspnea/shortness of breath, fatigue/tiredness, fever (>38.0°C), headache, 
lymphopenia (<1000 cells/mL), myalgia, nausea, oxygen saturation decrease by ≥3% from 
baseline,  rhinorrhea, sore throat, and sweats.   
Safety will be assessed by the frequency and severity of:  
1. Study product -related serious adverse events occurring from the time of the challenge 
through the end of the study (approximately 3 months post-challenge ). 
2. Clinical safety laboratory adverse events occurring from the time of CHI through study 
Day 8 . Parameters to be evaluated include: white blood cells (WBCs), absolute 
lymphocyte count  (except as part of MMID ), hemoglobin, platelets, and alanine 
transaminase (ALT), and creatinine (Cr).  
3. Adverse Events – non-serious adverse events occurring from the time of CHI through 
approximately 30 days post -challenge . See below for how adverse events are defined.  
 
9.1.1 Adverse Events (AEs)  
ICH E6 defines an AE as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product regardless of its causal relationship to the study 
treatment. FDA defines an AE as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product. The occurrence of an AE may come to the attention of study personnel during study 
visits and interviews of a study recipient presenting for medical care, or upon review by a study 
monitor.  
In this study, solicited symptoms of MMID will be collected from the time of CHI through 14 
days post -challenge  and will not be considered adverse events . Any influenza signs, symptoms  
or lab findings determined by the clinician to have  exceed ed the expected severity of MMID will 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  70 
CONFIDENTIAL  be considered unsolicited adverse events  and captured on the appropriate  data collection form 
and electronic case report form (eCRF) . Events  that are not  consistent with illness due to 
influenza will be considered unsolicited  AEs as well . Information to be collected for AEs 
includes event description, date of onset, assessment of severity,  relationship to study product 
and alternate etiology (assessed only by those with the training and authority to make a diagnosis  
and listed on the Form FDA 1572 as an investigator), date of resolution , seriousness and 
outcome. AEs occurring during the study will be documented appropriately regardless of 
relationship. AEs will be followed through resolution.  Resolution of an AE is defined as the 
return to pretreatment status or stabilization of the condition with the expectation that it will 
remain chronic.  
Any chronic or stable medical condition (Section  6.1) that is present at the time that the subject is 
screened will be considered as baseline and not reported as an AE. However, if the severity of 
any pre -existing medical condition increases, it should be recorded as an AE.  
9.1.1.1  Adverse Events Grading  
AEs must be assessed for severity and relationship to study product (see definitions below). AEs 
characterized as intermittent require documentation of onset and duration of each episode. The start and s top date of each reported AE will be recorded on the appropriate DCF and entered into 
the eCRF.  
Severity of Event: AEs will be assessed by a licensed study physician listed on the Form FDA 
1572 as the site PI or sub-investigator using a protocol -defined grading system (described below 
in this Section ). For events not included in the protocol -defined grading system, the following 
guidelines will be used to quantify severity:  
• Mild (Grade 1): Events require minimal or no treatment and do not interfere with the subject’s daily activities. 
 
• Moderate (Grade 2): Events result in a low level of inconvenience or concern with therapeutic measures. Moderate events may cause some interfe rence with functioning and 
daily activities. 
 
• Severe (Grade 3): Events interrupt the subject’s daily activities and may require systemic drug therapy or other treatment. Severe events are usually incapacitating.  
Relationship to Study Product: The licensed study physician’s assessment of an AE’s 
relationship to study product is part of the documentation process, but it is not a factor in determining what is or is not reported in this study. If there is any doubt as to whether a clinical observation is an AE,  the event should be reported. The relationship to study product must be 
assessed for AEs using the terms: related or not related. In a CHI, the study product must always 
be suspect. To help assess, the following guidelines are used:  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  71 
CONFIDENTIAL  • Related – There is a reasonable possibility that the study product caused the AE. Reasonable 
possibility means that there is evidence to suggest a causal relationship between the study 
product and the AE.  
• Not Related – There is not a reasonable possibility that the administration of the study 
product caused the event.  
Adverse Events Grading : All AEs and laboratory findings  (that are not part of MMID) will be 
graded for severity and assessed for relationship to study product  (see definitions). AEs 
characterized as intermittent require documentation of onset and duration of each episode. The 
start and stop date of each reported AE will be recorded on the appropriate data collection form 
and eCRF. Changes in the severity of an AE will be documented to allow an assessment of the 
duration of the event at each level of intensity.   
Oral temperature will be graded as follows:  
Table 7: Severity Grading for Oral Temperature 
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 38.1°C – 38.4°C  
100.6°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0°F  
*A fever can be considered not related to the study product if an alternative etiology can be 
documented.  
†Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to 
taking oral temperature  
Pulse , blood pressure , respiratory rate, and  SpO 2 will be graded as follows:  
Table 8: Pulse , BP, RR and SpO 2 Adverse Event Grading  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia – beats per 
minute  45 – 46  40 – 44 <40 
Tachycardia – beats per 
minute  100 – 130  131 – 155 >155  
Hypotension (systolic) 
mmHg  80 – 84  75 – 79 <75 
Hypotension (diastolic) 
mmHg  50 – 54  45 – 49 <45 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  72 
CONFIDENTIAL  Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Hypertension (systolic) 
mmHg  140 – 155  156 – 160 >160  
Hypertension (diastolic) 
mmHg  90 – 100  101 – 110 >110  
SpO 2 (%) 92-94  89-91  <89 
RR (increase) (bpm) 21-24  25-29  >30 
RR (decrease) (bpm)  9-11 6-8 <6 
Clinical safety laboratory values # will be graded as follows:  
Table 9: Clinical Safety and Laboratory AEs Grading  
Hematology  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC x 103/µL (Decrease)  2.50 – 3.69 1.50 – 2.49 <1.50  
WBC x 103/µL (Increase)  11.01 – 15.09  15.10 – 20.00 >20.00 
Absolute  Lymphocyte count  x 
103/µL (Decrease)  0.75 - 0.99 0.50 - 0.74 < 0.50  
Hgb g/dL (Decrease) (Female)  10.1 – 10.9 8.5 – 10.0 <8.5 
Hgb g/dL (Decrease) (Male)  11.0 – 12.4 9.5 – 10.9 <9.5 
Platelets cell  x 103/µL (Decrease) 
EDTA  140 – 162 100 – 139 <100  
Platelets x 103/µL (Increase) 
EDTA  376 – 550 551– 750 >750  
Platelets K/cu mm (Decrease) 
Citrate  115-124 100-114 <100  
Platelets K/cu mm (Increase) 
Citrate  376 - 550 551-750 >750  
Chemistry  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
ALT IU/L (Increase) (Female)  44 – 100  101 – 2 00 >200 
ALT IU/L (Increase) (Male)  61- 138 139 – 275 >275 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  73 
CONFIDENTIAL  Creatinine mg/dL (Increase)  1.5 – 1.8 1.9 – 2.2 > 2.2  
 
9.1.2 Serious Adverse Events (SAEs)  
An AE or suspected adverse reaction is considered a SAE if, in the view of either the site 
principal investigator or Sponsor , it results in any of the following outcomes:  
• Death,  
• a life -threatening adverse event1,  
• inpatient hospitalization or prolongation of existing hospitalization,  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
• a congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical judgment 
they may jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an ER or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse.  
1 Life-threatening adverse event. An AE is considered “life-threatening” if, in the view of either 
the site principal investigator or Sponsor , its occurrence places the patient or subject at 
immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death.  
SAEs will be:  
• Assessed for severity and relationship to study product and alternate etiology (if not related 
to study product) by a licensed study physician listed on the Form FDA 1572 or by the Institution as the site Principal Investigator or Sub -Investigator.  
• Recorded on the appropriate SAE data collection form and eCRF.  
• Followed through resolution by a licensed study physician (for investigational new drug application  [IND] studies, a physician listed on the Form FDA 1572 as the site Principal 
Investigator or Sub-Investigator).  
• Reviewed and evaluated by DMID, an Independent Safety Monitor (ISM) (as deemed 
necessary), the Safety Monitoring Committee (SMC) (periodic revi ew unless related), and 
the IRB/IEC.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  74 
CONFIDENTIAL  
 Procedures to be Followed in the Event of Abnormal Laboratory 
Test Values or Abnormal Clinical Findings  
The site PI or designated clinician licensed to make medical diagnoses and listed on Form FDA 
1572 is responsible for recording all AE/SAEs that are  observed or reported during this study, 
regardless of relationship to study product. AE/SAEs,  abnormal laboratory test values or 
abnormal clinical findings will be collected, assessed,  documented, reported, and followed 
appropriately, using a local laboratory as necessary. In determining eligibility, refer to 6.1and the 
protocol -specific MOP.  
 Specification of Safety Parameters  
Safety will be assessed by the frequency and severity of:  
Solicited Symptoms : Influenza symptoms  elicited  by the  Flu-PRO Survey Instrument and 
Validation Diary  (Appendix D ).  
Unsolicited Events : Unsolicited events are any non-serious adverse events occurring from the 
time of CHI through approximately 30 days post -challenge . 
 Reporting Procedures  
9.4.1 Reporting Serious Adverse Events  
Any AE that meets a protocol -defined serious criterion must be submitted immediately (within 
24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the 
following address:  
 
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650 
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1-301-897 -1709 (outside  US) 
SAE FAX Number: 1 -800-275-7619 (US) or 1-301- 897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
In addition to the SAE form, select SAE data fields must also be entered into the DCC system . 
Please see the protocol -specific MOP for details regarding this procedure.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  75 
CONFIDENTIAL  Other supporting documentation of the event may be requested by the DMID Pharmacovigilance 
Group and should be provided as soon as possible.  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group.  The DMID Medical Monitor and DMID 
Clinical Project Manager will be notified of the SAE by the DMID Pharmacovigilance Group.  
The DMID Medical Monitor will review and assess the SAE for regulatory reporting and 
potential impact on study subject safety and protocol conduct.  
At any time after completion of the study, if the site principal investigator or designated clinician 
licensed to make medical diagnoses and listed on Form FDA 1572 becomes aware of an SAE 
that is suspected to be related to study product, the site principal investigator  or designated 
clinician licensed to make medical diagnoses and listed on Form FDA 1572 will report the event 
to the DMID Pharmacovigilance Group.  
9.4.2 Regulatory Reporting for  Studies Conducted Under DMID  Sponsored- IND 
Following notification from the site P I or designated clinician licensed to make medical 
diagnoses and listed on Form FDA 15721572, DMID, as the IND Sponsor , will report any 
suspected unexpected SAE . DMID will report an AE as a suspected unexpected AE only if there 
is evidence to suggest a causal relationship between the study intervention and the AE.  DMID 
will submit an IND safety report to the FDA and will notify all participating site P Is (i.e., all  PIs 
to whom the Sponsor is providing drug under its IND(s) or under any PI’s IND(s)  of potential 
serious risks from clinical studies or any other source, as soon as possible.  DMID will report to 
the FDA any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, 
but in no case later than seven  calendar days after the Sponsor’s initial receipt of the information.  
If the event is not fatal or life -threatening the IND safety report will be submitted within 15 
calendar days after t he Sponsor determines that the information qualifies for reporting as 
specified in 21 CFR Part 312.32.  Relevant follow up information to an IND safety report will be 
submitted as soon as the information is available.  Upon request from FDA, DMID will submit  to 
the FDA any additional data or information that the agency deems necessary, as soon as possible, 
but in no case later than 15 calendar days after receiving the request.   
All SAEs designated as “not related” to study product(s), will be reported to the FDA at least 
annually in a summary format.  
9.4.3 Reporting of Pregnancy  
Pregnancies occurring in study subjects will be reported via Advantage electronic data capture 
system (Advantage  eClinical) on the Pregnancy Report form.  No further study product  will be 
administered to pregnant subjects, but with the subject’s permission a venous blood sample for serological assays will be collected per protocol, however large volume blood samples for 
cellular immunological assays will be discontinued ,  and the subject will continue to be followed 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  76 
CONFIDENTIAL  for safety for the duration of this study. Efforts will be made to follow all pregnancies reported 
during the course of this study to pregnancy outcome pending the subject’s permission. 
 Type and Duration of Follow -up of Subjects after Adverse Events  
AEs will be assessed (per Section 9.1.1 ) and followed from initial recognition of the AE through 
end of the protocol defined follow -up period.  
SAEs will be followed up through resolution even if duration of follow -up goes beyond the 
protocol -defined the follow -up period.  
Resolution of an AE is defined as the return to pre -treatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
 Halting Rules  
9.6.1 Study Halting Criteria  
Additional enrollment and study interventions/administration of study products in this study will 
be halted for Safety Monitoring Committee (SMC) review/recommendation if any of the 
following are reported:  
1. Any subject experiences laryngospasm, bronchospasm, or anaphylaxis within one day 
after challenge.  
2. Four  or more subjects (approximately ≥5%  of the anticipated sample size)  experience the 
same related grade 3 AE of any kind after challenge through the inpatient unit period and 
related to study product.  
3. Two or more subjects experience generalized urticaria (defined as occurring at more than two body parts) within three days after challenge.  
4. Any subject experiences a related SAE during the inpatient unit period.  
5. Any subject develops severe influenza (Section  2.3.2 ) during the inpatient unit period and 
requires admission to an Intensive Care Unit (ICU), and/or receipt of ICU level of care.  
6. Any medically significant safety issue that the PI determines should halt the study. 
 Safety Oversight  
9.7.1 Safety Monitoring Committee (SMC)  
This clinical study will utilize an SMC, which is an independent group of experts that advises the 
DMID. The primary responsibility of the SMC is to monitor subject safety. The SMC is e xternal 
to the DMID and comprises at least 3 voting members. The SMC will consist of members with appropriate expertise to contribute to the interpretation of the data from this study. Its activities 
will be delineated in a SMC charter that will describe the membership, responsibilities, and the 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  77 
CONFIDENTIAL  scope and frequency of data reviews. The SMC will operate on a conflict -free basis 
independently of the study team. The DMID or the SMC may convene ad hoc meetings of the 
SMC according to protocol criteria or if there are concerns that arise during the study.  
As defined in the charter, the SMC will review data at specified times during the course of the 
study for subject and overall study progress and will conduct ad hoc reviews as appropriate when 
a halting rule is met or for immediate concerns regarding observations during this study.  The 
SMC will hold the following meetings; an organizational meeting prior to subject enrollment , 
any ad hoc meetings  when a halting rule  is met or  due to specific safety issues as the SMC deems 
necessary, and a final meeting to review cumulative safety data.   
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  78 
CONFIDENTIAL  
 HUMAN SUBJECTS PROTECTION  
 Institutional Review Board/Independent Ethics Committee  
Each institution engaged in this research will hold a current Federal Wide Assurance (FWA)  
issued by the Office for Human Research Protections (OHRP) for federally funded research. The  
IRB must be registered with OHRP [OHRP -only or OHRP/FDA] as applicable to the research.  
The IRB FWA number will be provided to DMID.  
 
Each site PI will obtain IRB approval for this protocol to be conducted at his/her research site(s) 
and send supporting documentation to the DMID before initiating recruitment of subjects.  The 
investigator will submit applicable information to the IRB/IEC on which it relies for the review, 
to conduct the review in accordance with 45 CFR 46, ICH E6 GCP, and as applicable,  21 CFR 
56 (Institutional Review Boards) and 21 CFR 50 (Protection of Human Subjects) , other federal, 
state, and local regulations. The  IRB/IEC must be  registered with OHRP as applicable to the 
research.  DMID  must receive the documentation that verifies IRB/IEC -approval for this 
protocol, associated informed consent documents, and upon request any recruitment material and 
handouts or surveys intended for the subjects, prior to the recruitment and enrollment of subjects.  
Any amendments to the protocol or consent materials will be approved by the IRB/IEC before 
they are implemented.  IRB/IEC review and approval will occur at least annually throughout the 
enrollment and follow -up of subjects and may cease if annual review is no longer required by 
applicable regulations  and the IRB/IEC. The investigator will notify the IRB/IEC of deviations 
from the protocol and reportable SAEs, as applicable to the  IRB/IEC policy.  
 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
study and continuing throughout the individual’s study participation.  During recruitment,  
investigator or designee  may obtain information regarding eligibility through oral or written 
communication with the prospective subject. The screening may occur by phone using an IRB approved process that ensures confidentiality . The information obtained from this phone call 
assessment will remain locally at the site and will not be entered into the Advantage EDC data 
base unless the subject is enrolled.  
At the first screening visit before any study proced ures are performed, informed consent will be 
obtained and documented.  Subjects will receive a concise and focused presentation of key 
information about the study, verbally and with a written consent form.  The explanation will be 
organized and presented in lay terminology and language that facilitates understanding why one 
might or might not want to participate.  
An investigator or designee will describe the protocol to potential subjects face -to-face.  The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  79 
CONFIDENTIAL  risks and  discomforts, any expected benefits to the subject, and alternative treatment will be 
presented first to the subject.  The subject will be asked to consent specifically to genetic testing 
(HLA testing  and transcriptomics) planned for this study.  
Subjects will also receive an explanation that the study involves research, and a detailed 
summary of the proposed study procedures and study interventions/products.  This will include 
aspects of the study that are experimental, the probability for random assignment t o treatment 
groups, any expected benefits, all possible risks (including a statement that the particular 
treatment or procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may become pregnant, that are currently unforeseeable), the expected duration of the subject’s 
participation in the study, alternative procedures that may be available and the important 
potential benefits and risks of these available alternative procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes 
available that may be relevant to their willingness to continue participation in the study. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are 
available if injury occurs, and, if so, what they consist of, or where further information may be obtained.  Subjects will be informed of the anticipated financial expenses, if any, to the subject 
for participating in the study, as well as any anticipated prorated paymen ts, if any, to the subject 
for participating in the study. They will be informed of whom to contact ( e.g., the investigator) 
for answers to any questions relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the 
subject’s participation in the study may be terminated.  The subjects will be informed that 
participation is voluntary and that they are free to withdraw from the study for any reason at any 
time without penalty or loss of benefits t o which the subject is otherwise entitled.   
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed.  Subjects will be informed 
that the monitor(s ), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct 
access to the subject’s original medical records for verification of study procedures and/or data 
without violating the confidentiality of the subject, to the extent permitted by the applicable laws 
and regulations, and that, by signing a written informed consent form, the subject is authorizing such access.  
Subjects will be in formed that records identifying the subject will be kept confidential, and, to 
the extent permitted by the applicable laws and/or regulations, will not be made publicly 
available and, if the results of the study are published, the subject’s identity will r emain 
confidential.  Subjects will be informed whether private information collected from this research 
and/or specimens will be used for additional research, even if identifiers are removed.   
Subjects will be allowed sufficient time to consider participation in this research study and have 
the opportunity to discuss this study with their family, friends or legally authorized 
representative, or think about it prior to agreeing to participate.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  80 
CONFIDENTIAL  Informed consent forms will be IRB-approved, and subjects will be asked to read and review the 
consent form. Subjects must sign the informed consent form prior to starting any study 
procedures being done specifically for this study. 
Once signed, a copy of the informed consent form will be given to the subject(s) for thei r 
records. The subject(s) may withdraw consent at any time throughout the course of the study. 
The rights and welfare of the subject(s) will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they d ecline to participate in this study.  
Study personnel may employ recruitment efforts prior to obtaining study consent if a patient -
specific screening consent is on record or if the IRB has agreed that chart review is allowed 
without a fully executed screening consent.  In cases where there is not a patient -specific 
screening consent on record, site clinical staff  may pre -screen via chart review and refer potential 
subjects to the Research staff.  Research staff would obtain written consent per the standard 
informed consent process before conducting protocol -specific activities.  
New information will be communicated by the site principal investigator to subjects who consent to participate in this study in accordance with IRB requirements.  The informed consent 
document will be updated,  and subjects will be re -consented per IRB requirements, if necessary.  
Subjects will be given a copy of all informed consent forms that they sign.  
 Consent for Future Use of Stored Specimens and Data  
Subjects who agree to participate in this study will have venous blood collected for clinical 
safety laboratory evaluations, serological and cellular immunology assays, as well as for  
transcriptomic profiling assessments. The amount of venous blood collect ed for these  assays may 
exceed the amount required to perform per protocol (PP)  defined assays, and this excess/residual 
blood and corresponding serum, plasma and PBMC s will be designated for future  research use 
and stored indefinitely at a central storage facility. Similarly,  subjects will also have NP swabs 
and NLF  collected for clinical laboratory evaluations and immunology assays. The NP swab  
supernatant  can be stored after it is used  to test for respiratory viruses. The NLF  collected for 
immunology assays exceeds the amount required to perform per protocol (PP) defined assays. 
The NP swabs and NLF  excess/residual fluid and corresponding isolated cells will be designated 
for future research use and stored indefinitely at a central storage facility.  
Samples designated for future  research use may be used to determine additional immunological 
assessments that may include  but are not limited to antibody epitope mapping, B and T cell 
repertoire determination, nontraditional  immune assay development, determination of innate 
immune factors and the ability of  challenge virus -induced antibodies to cross -react to different 
influenza proteins and virus strains. These blood samples might be used in new or different 
immunological laboratory tests, to provide  information for the development of new vaccin es, or 
for the studies of influenza or other  infections. Subjects will be asked to consent specifically to 
future genetic testin g, including whole genome sequencing An IRB will review future research 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  81 
CONFIDENTIAL  prior to the use of identifiable specimens or data. Future research use specimens, upon written 
request and approval from DMID, may be shared with investigators at the participating VTEU 
sites, with other investigators  or company designated research laboratories for purposes of 
conducting additional  immunological assessments other than PP analysis. DMID would 
authorize shipment from the  DMID CMS . There are no benefits to subjects in the collection, 
storage and future research use  of their samples/specimens. Future research use 
samples/specimens will not be sold or used directly for production of any commercial product . 
Each  sample/specimen will be encoded (labeled) only with a barcode and a unique tracking 
number to protect  subject confidentiality. Reports from future research studies performed using 
subjects’  samples/specimens will NOT be kept in their health records.  
Subjects will be asked to consent to the future research use of excess/residual specimens at the 
time of enrollment. Subjects will be asked to consent to sharing genetic information and samples . 
Subjects may withdraw permission to use samples for future use at any time. They will need to  
contact the study site and the samples will be removed from the study repository after this study is completed and documentation will be completed that outlines the reason for withdrawal of  
permission for future us e of samples.  
 Exclusion of Women, Minorities, and Children (Special Populations)  
This study will be inclusive of all healthy adults who meet the inclusion/exclusion criteria, 
regardless of religion, sex, or ethnic background.   
 Subject Confidentiality  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and 
the Sponsor (s) and their agents.  This confidentiality includes documentation, investigation data, 
subject’s clinical information, and all other information g enerated during participation in the 
study.  No information concerning the study or the data generated from the study will be released 
to any unauthorized third party without prior written approval of the DMID and the subject.  
Subject confidentiality will b e maintained when study results are published or discussed in 
conferences.  The study monitor or other authorized representatives of the Sponsor  or 
governmental regulatory agencies may inspect all documents and records required to be maintained by the inves tigator, including but not limited to, medical records (office, clinic, or 
hospital) and pharmacy records for the subjects in this study.  The clinical study site will permit 
access to such records.  
All records will be kept locked and all computer entry and networking programs will be carried 
out with coded numbers only and with password protected systems.  All non -clinical specimens, 
evaluation forms, reports, and other records that leave the site will be identified only by a coded 
number.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  82 
CONFIDENTIAL  
 Certificate of Con fidentiality  
To protect privacy, we have received a Certificate of Confidentiality.  With this Certificate, the 
researchers cannot be forced to release information that may identify the research subject, even 
by a court subpoena, in any federal, state, or l ocal civil, criminal, administrative, legislative, or 
other proceedings.  The researchers will use the Certificate to resist any demands for information 
that would identify the subject, except as explained below.  
The Certificate cannot be used to resist a d emand for information from personnel of the United 
States Government that is used for auditing or evaluation of federally funded projects, like this study, or for information that must be released in order to meet the requirements of the Federal 
Food and Drug Administration (FDA).  
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
information about themselves or their involvement in this research.  If any person or agency 
obtains a written consent to receive research inf ormation, then the researchers may not use the 
Certificate to withhold that information.  
The Certificate of Confidentiality does not prevent the researchers from reporting without the subject’s consent, information that would identify the subject as a subject in the research project 
regarding matters that must be legally reported including: child and elder abuse, sexual abuse, or wanting to harm themselves or others.  
The release of individual private information or specimens for other research will only occur if 
c
onsent was obtained from the individual to whom the information, document, or biospecimen 
pertains, or for the purposes of other research that is in compliance with applicable Federal 
regulations governing the protection of human subjects in rese arch.  
 Costs, Subject Compensation, and Research Related Injuries  
There is no cost to subjects for the research tests, procedures, and study product while taking part 
in this study. Procedures and treatment for clinical care may be billed to the subject, su bject’s 
insurance or third party.  Subjects may be compensated for their participation in this study. 
Compensation will be in accordance with the local IRB’s policies and procedures, and subject to 
IRB approval.  
If it is determined by the site principal inv estigator that an injury occurred to a subject as a direct 
result of the tests or treatments that are done for this study, then referrals to appropriate health 
care facilities will be provided to the subject.  Study personnel will try to reduce, control, and 
treat any complications from this study. Immediate medical treatment may be provided by the 
participating site.  No financial compensation will be provided to the subject by the NIAID, NIH 
to the subject, or by the participating site for any injury suffered due to participation in this study. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  83 
CONFIDENTIAL  
 STATISTICAL CONSIDERATIONS  
 Introduction  
The goal of this study is to assess the impact of pre -existing immunity to 
A/California/04/2009/H1N1 Variant Influenza A virus on clinical responses and immune 
responses after subjects are challenged intranasally with 2 mL of approximately 5x106 tissue 
culture infective dose ( TCID 50) of the virus.  The study will evaluate and further refine the H1N1 
CHI model across multiple sites, which will help develop the model for future vaccin e studies.  
 Study Hypotheses  
This study is not designed to achieve pre-set levels of power and precision to address the 
primary, secondary, or exploratory objectives.  The power and precision allowed by the study’s 
sample size are discussed in Section  11.3, and the general methodology planned to address study 
objectives is described in Section  11.5. Specific null and alternative hypotheses and details about 
planned tables, figures, and data listings will be defined in a separate statistical analysis plan.  
 Sample Size Considerations  
11.3.1  Study  Design  
This is a CHI study of A/Bethesda/MM2/H1N1 virus infection to assess clinical response, 
immunological response, and safety. A total of up to 80 participants will receive controlled 
A/Bethesda/MM2/H1N1 virus inoculation.  
Influenza A/Bethesda/MM2/H1N1 challenge will be performed using a 2 mL dose of 
approximately 5x106 TCID 50/mL. The primary objective of the study will be to evaluate the 
association of symptomatic RT -PCR -positive influenza virus infection post -challenge and pre -
existing HAI antibody titers in healthy subjects.  
Details of the study design are presented in Section  4, and the schedule of events is given in 
Appendix A  (Table 11). 
11.3.2  Sample Size  
The study is planned to enroll up to 80 subjects, all of whom will receive the study influenza 
challenge virus.  While the study is not designed to test any specific null hypothesis or reach a 
pre-determined level of estimation precision, the following gives the precision and power for estimates and hypothesis tests of interest, respectively, based on this proposed sample size.  
Adjustments to p -values in the presence of multiple comparisons may be made, depending on the 
objective, but the calculations below do not  account for this possibility.  Details on adjustment for 
multiple comparisons will be described in the statistical analysis plan.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  84 
CONFIDENTIAL  The primary objective is to evaluate the association between pre -existing (baseline) HAI  
antibody titers and MMID post -challenge.  Table 9 below gives the power to detect varying 
decreases in the odds of a binary endpoint such as MMID with a one standard deviation (SD) 
increase in a continuous covariate (assumed to be normally distributed) among all subjects 
(n=80), via a Wald test from a logistic regression model at the α=0.05-level. This would roughly 
correspond to testing for an association between log-transformed baseline HAI titer and MMID.  
Table  10: Power to detect odds ratios (OR) for a one SD increase in a continuous, 
normally distributed covariate in a logistic regression model at the α=0.05-level  
 Power (%)  
Prevalence*  OR=0.4  OR=0.5  OR=0.6  OR=0.7  
0.5 96.1 82.8 59.1 34.2 
0.6 95.5 81.3 57.3 32.9 
0.7 94.9 79.6 55.1 31.3 
*The probability of a binary outcome such as MMID within the study population 
Table 10 indicates the probability of observing one or more safety events, suc h as a solicited 
symptom or an SAE of a particular classification in all subjects (n=80), given underlying event 
probabilit ies. 
Table 11: Probability (%) of observing at least one safety event, given varying 
underlying event probabilities and group sizes  
True Event Probability  All Subjects  
(N=80)  
10% (very common)  >99.9  
1% (common)  55.2 
0.1% (uncommon)  7.7 
0.01% (rare)  0.8 
 
Binomial confidence intervals (CI) are widest (have the least precision) when the response rate  
is 50%. With this event rate among all subjects (40 events among n=80 subjects), the 
corresponding exact Clopper -Pearson CI w ould be (38.6%, 61.4%).  
 Planned Interim Analyses  
Interim analyses would only be used to terminate this trial in the event that unanticipated safety  
events were determined to be of sufficient concern to require such action by the sponsor. These  
assessments will not be made on the basis of testing a formal statistical hypothesis. As described 
in Section  9.7, an SMC will be convened by DMID to review partic ipant, clinical, and safety 
data.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  85 
CONFIDENTIAL  11.4.1  Interim Safety Review  
An interim safety review may include enrollment and demographic information, clinical 
laboratory tests, reported influenza symptoms, and AE/SAEs. Additional data may be requested by the SMC, and inte rim statistical reports may be generated as deemed necessary and 
appropriate by DMID.  The SMC will meet and review these data at scheduled time points or ad 
hoc as needed during this trial, as delineated in the SMC charter. As an outcome of each review, 
the SMC will make a recommendation to continue, modify, or terminate this study. The trial will 
also be monitored to determine if any of the halting rules in Section  11.4.1are met, and if so , the 
SMC will be convened to review.  
 Final Analysis Plan  
Clinical, safety, and  immunology data through the last follow -up at Day 91 will comprise the 
primary clinical databa se for this study.  Once the last subject has completed the final telephone 
follow -up, the primary clinical database will be cleaned, monitored, and locked.  Analyses of 
safety, clinical, and available immunological data will be performed by the SDCC after t he 
primary clinical database is locked and the detailed statistical analysis plan is finalized.  
The CSR will be completed when all primary and secondary safety, clinical, and immunological 
endpoint data are available. Any available data from the explorator y endpoints may also be 
included. Additional exploratory endpoint data may be included in an addendum to the CSR , 
publication of manuscript(s), or other report. 
A formal statistical analysis plan  (SAP)  that elaborates on the analyses indicated here will be  
developed and finalized prior to performing the final analysis.  
11.5.1  Analysis Populations  
The Safety Analysis (SA) population will include all subjects who received the study influenza challenge.  
The modified Intent -to-Treat (mITT) population will consist of a ll subjects who received the 
study influenza challenge and were followed for the entire challenge period of the study.  
The Per -Protocol (PP) population will include all subjects in the mITT population with the 
following exclusions:  
• Data from all available visits for subjects found to be ineligible at baseline  
• Data from any visit that occurs substantially out of window  
• Data from all visits subsequent to:  
o Major protocol deviations  
o Receipt of immunosuppression or any medications that may be associated with impaired responsiveness  
o Receipt of any investigational drug/investigational vaccin e/licensed vaccin e 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  86 
CONFIDENTIAL  o Receipt of blood or blood products, or blood donation  
The Infected (INF) population will include only the infected subjects (i.e. those with detectable 
influe nza virus) from the PP population.  
The Symptomatic (SYMP) population will include only the subjects from the PP population who report symptoms throughout the challenge period.  
11.5.2  Safety and Clinical Data 
Summaries of safety and clinical data will be presented for the SA population.  Analysis 
involving endpoints calculated over the course of the entire challenge period (e.g. MMID) will be done within the mITT population, or the PP, INF, or SYMP populations as appropriate.  
Binary safety and clinical outcomes such as influenza infection, MMID, solicited symptoms, and 
SAEs will be presented as frequencies and percentages.  Results will be presented overall and by 
infection status, and separately by study day where applicable. Associated confidence intervals and comparisons between infected and uninfected subjects via exact binomial tests will also be 
included, as appropriate.  
Viral shedding will be summarized over the challenge period with the following: a binary yes/no 
variabl e separately by inpatient study day (Day 1 through Day 8) and over the entire challenge 
period; peak (quantitative) shedding and total shedding, as measured by the area under the curve 
(AUC) over the challenge period; the total number of days of shedding.  
Solicited symptoms of influenza recorded via the Flu-PRO survey instrument will be 
summarized by extent (not at all, a little bit, somewhat, quite a bit, very much) for each study 
day, the maximum extent over the first 8 days, and the maximum extent over the entire study. 
Symptoms will also be analyzed by treating the extent as an ordinal variable (0=not at all, 1=a little bit, etc.) and calculating the mean scores in each domain (e.g. nose, throat, etc.) and across 
all collected symptoms.  Symptoms will als o be analyzed by taking the most extensive response 
over the follow -up period and dichotomizing into a binary variable (not at all versus at least a 
little bit) and using standard techniques, such as exact confidence intervals, to summarize the proportion of subjects reporting each symptom. Analysis of reported symptoms will be presented 
across all subjects and by infection status (RT -PCR -confirmed symptomatic, RT -PCR -confirmed 
asymptomatic, RT-PCR -negative symptomatic, RT -PCR -negative asymptomatic), and su bjects 
may be compared by infection status using appropriate hypothesis tests. The  Flu-PRO Survey 
Instrument will be assessed for its accuracy in predicting infection status in an exploratory 
analysis, by randomly splitting the data into training and testing data.  
Unsolicited AEs will be coded by Medical Dictionary for Regulatory Activities (MedDRA) for  
preferred term (PT) and system organ class (SOC). SAEs  will be reported by detailed listings 
showing the event description, MedDRA preferred term and SOC, r elevant dates (challenge 
dates and AE onset dates), severity, relatedness, and outcome for each event. Non-serious 
unsolicited AEs will be summarized as number and percentage of subjects reporting at least one 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  87 
CONFIDENTIAL  event in each MedDRA SOC and PT, cross tabulat ed by severity and relationship to the 
influenza challenge. Additionally, the proportion of subjects and exact 95% confidence intervals 
of AEs in aggregate and by MedDRA categories will be computed.  SAEs will be described by 
visit, over the challenge period and over the entire study.  
Clinical laboratory data will be summarized by severity for each visit and as the maximum over  
all visits. Graphical presentations may include box plots and plots of changes from pre -infection 
measurements.  
11.5.3  Immunological Data 
Analysis of the primary objective will be done in both the mITT and PP populations, the latter as 
a sensitivity analysis. Analysis of secondary and exploratory immunological objectives will be done in the PP, INF, and/or SYMP populations, as appropriate.  
The associations between MMID and variable baseline HAI titers (the primary analysis) will be 
assessed in the PP population via logistic regression, treating baseline titer as a continuous variable after appropriate transformation.  Associations between other  infection -related endpoints 
(secondary outcomes: asymptomatic infection; symptoms without detected influenza virus) and 
baseline HAI, NAI, or MN antibody titers will be assessed similarly.  For asymptomatic 
infection, the analysis will be performed in the INF population to evaluate the likelihood of symptoms given influenza infection; for symptoms without detected influenza virus, the analysis 
will be performed in the SYMP population to evaluate the likelihood of infection given reported symptoms.  
Study str ain-specific immune responses will be summarized at each relevant study visit, overall 
and by infection status. Analyses for antibody titers will include the number and proportion of subjects with a titer ≥1:40, number and proportion of subjects achieving seroconversion (defined 
as either a pre-challenge titer <1:10 and a post -challenge titer ≥1:40 or a pre -challenge titer 
≥1:10 and a minimum four -fold rise in post -challenge antibody titer), and  
Geometric Mean Titers (GMTs) along with corresponding 95% conf idence intervals. Descriptive  
summary statistics will be provided for all assays and time points. The correlation between HAI,  
MN, and NAI antibody titers will be evaluated. Plots such as reverse cumulative distributions or  
longitudinal presentations of GM Ts will be presented.  
Exploratory objectives also include evaluating the associations between MMID and baseline 
HAI titers, as well as potential confounders age, sex, and receipt of seasonal influenza vaccin e in 
the previous year.  This will be assessed via  multivariable logistic regression in the PP 
population.  
Assays measured on continuous scales will be summarized by the mean, median, standard deviation, and range.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  88 
CONFIDENTIAL  11.5.1  Transcriptomic Data  
For the transcriptomics exploratory analysis, sequencing data will be pre-processed by removing 
adapters and low -quality reads and mapping sequences to the latest human reference genome 
using splice -aware alignment software such as HISAT2 [44]. Gene expres sion quantification will 
be carried out by using the Subread software [45] using the latest Ensembl [46] gene model 
annotations as a reference. Systematic differences in sequence coverage between samples will be 
accounted for using the TMM method [47] as implemented in the edgeR  [48] R package. 
Principal component analysis, non-metric multidimensional scaling, and hierarchical clustering 
analysis will be used to identify potential global outliers and systematic b atch effect. Negative 
binomial models as implemented in edgeR  [48] will be used to identify genes for each post -
challenge day that were differentially expressed (DE) compared to pre -chall enge. To control for 
testing multiple genes, the false -discovery rate (FDR) based on the Benjamini -Hochberg 
procedure [49] as implemented in the p.adjust  R function will be applied. Genes with a FDR -
adjusted p-value < 0.05 will be deemed to be significantly DE. The pvclust  [50]R package will 
be applied to identify co-expressed DE gene clusters and cluster time trends will be visualized . 
Pathway enrichment analysis based on the latest MSigDB [51] and KEGG [52]databases as well 
as Blood Transcription Modules [53]  accounting for gene length bias will be carried out using 
the implementation provided by the goseq  [54] R package. Pathway maps color -coded by 
challenge effect will be provided for significantly enriched KEGG pathways. In addition, for each enriched pathway, time trends of the median of the average pathway response will be visualized. Additional details/analyses will be desc ribed in the SAP.  
11.5.2  Genomics Data  
To assess the association of subject HLA class I and II alleles with development of MMID post -
challenge through Day 8, pre -existing immune status, and magnitude and breadth of the elicited 
immune responses post-challenge, regularized logistic regression (for binary outcomes) and 
regularized linear regression (for continuous outcomes) using HLA alleles as predictors as implemented in the  glmnet  [55] R packages  will be utilized. C ross-validation will be used to 
select optimal regularization parameters. Additional details/analyses will be described in the 
SAP.  
11.5.3  Missing Values and Outliers  
All attempts will be made to collect all data per protocol. If all Flu-PRO Survey Instrument data 
for one study day are missing, the missingness will be indicated in related summaries, but no 
imputation is planned for endpoints derived from these data (e.g. MMID).  No imputation for 
missing immunological or transcriptomic/genomic data is planned either.  
Any data point that appears to be erroneous or inexplicable based on clinical judgment will be 
investigated as a possible outlier. If data points are identified as outliers, sensitivity analyses will 
be performed to examine the impact of including or excluding the outliers. Any substantive differences in these analyses will be reported.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  89 
CONFIDENTIAL  
 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records in compliance 
with ICH E6, Section  4.9 and regulatory and institutional requirements for the protection of 
confidentiality of subjects.  Each site will permit authorized represen tatives of the DMID, its 
designees, and appropriate regulatory agencies to examine (and when required by applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of 
the study safety and progress.  These  representatives will be permitted access to all source data 
and source documents, which include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ memory aids or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions certified 
after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept at the pharmacy, at the laboratories, 
and medico -technical departments involved in the study.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  90 
CONFIDENTIAL  
 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each participating site (s) and 
its subcontractors are  respon sible for conducting routine quality assurance (QA) and quality 
control (QC) activities to internally monitor study progress and protocol compliance.  The site 
principal investigator will provide direct access to all study -related sites, source data/data 
collection forms, and reports for the purpose of monitoring and auditing by the Sponsor , and 
inspection by local and regulatory authorities.  The site principal investigator will ensure all study 
personnel are appropriately trained and current documentations are maintained on site.  
The DCC will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database.  Any missing data or data 
anomalies will be communicated to the participating site(s) for clarification and resolution.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  91 
CONFIDENTIAL  
 DATA HANDLING AND RECORD KEEPING  
 Data Management Responsibilities  
The investigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of 
the data reported.  All source documents should be completed in a neat, legible manner to ensure 
accurate interpretation of data.  Black  or blue permanent  ink is required to ensure clarity of 
reproduced copies.  When making changes or corrections, cross out the original entry with a 
single line, and initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copies of the eCRF will be provided for use as source data collection forms  and maintained for 
recording data for each subject enrolled in the st udy. Data reported in the eCRF derived from 
source data collection forms  should be consistent or the discrepancies should be explained.  
The Sponsor  and/or its designee will provide guidance to the site principal investigators and 
other study personnel on making corrections to the data collection forms and eCRF. 
 Data Coordinating Center/Biostatistician Responsibilities  
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site principal investigator. During the study, the site principal 
investigator must maintain complete and accurate documentation for the study.  
The data coordinating center  for this study will be responsible for data management, quality 
review, analysis, and reporting of the study data.  
 Data Capture Methods  
Clinical information  (including, but not limited to, AE/SAEs, concomitant medications, receipt 
of 2018/2019 influenza vaccine, receipt of non-seasonal influenza vaccine, including those that 
are experimental,  product type, vaccine virus strains and approximate date of vaccination 
(Section 7.1.1 ) will be recorded on the appropriate DCF,  medical history, physical assessments, 
and clinical laboratory values ) will be collected on data collection forms by study personnel then 
entered into eCRFs via a 21 CFR Part 11-compliant internet data entry system  provided by the 
study data coordinating center . The data system includes password protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.   
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  92 
CONFIDENTIAL  
 Types of Data  
Data for this study will include clinical, safety, and outcome measures ( e.g., clinical laboratory 
values, and immunological data).  
 Study Records Retention  
Study records and reports including, but not limited to, eCRFs, source documents, ICFs,  
laboratory test results,  and study drug disposition records will be retained  for 2 years after a 
marketing application is approved for the study product  for the indication for which it is being 
investigated; or, if no application is to be filed or if the application is not approved for the study 
product , until 2 years after the investigation is discontinued and the FDA has been notified. 
These documents will be retained for a longer period, however, if required by local regulations. 
ICFs for future use will be maintained as long a s the sample/specimen exists.  
No records will be destroyed without the written consent of the Sponsor . It is the responsibility 
of the Sponsor  to inform the site principal investigator when these documents no longer need to 
be retained. The participating VTEU sites must contact DMID for authorization prior to the 
destruction of any study records.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  93 
CONFIDENTIAL  
 CLINICAL MONITORING  
Site monitoring is conducted to ensure that the human subjects’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet Sponsor , ICH/GCP guidelines and applicable regulations, and that this study is 
conducted in accordance with the protocol, protocol -specific MOP and applicable Sponsor 
standard operating procedure s. DMID, the sponsoring agency, or its designee will conduct site -
monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by DMID and may be made more 
frequently as directed by DMID.  Monitori ng visits will include, but are not limited to, review of 
regulatory files, accountability records, eCRFs, informed consent forms, medical and laboratory 
reports, and protocol and GCP compliance.  Site monitors will have access to each participating 
site, s tudy personnel, and all study documentation according to the DMID -approved site 
monitoring plan.  Study monitors will meet with site principal investigators to discuss any 
problems and actions to be taken and will document site visit findings and discussions.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  94 
CONFIDENTIAL  
 PUBLICATION POLICY  
Following completion of the study, the lead Principal Investigator is expected to publish the 
results of this research in a scientific journal.  All investigators funded by the NIH must submit or 
have submitted for them to the National Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic version of their final, peer -reviewed 
manuscripts upon acceptance for publication, to be made publicly available no later than 12 
months after the official date of publication.  The NIH Public Access Policy ensures the public 
has access to the published results of NIH funded research.  It requires investigators to submit 
final peer -reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed 
Central upon acceptance for publication.  Further, the policy stipulates that these papers must be 
accessible to the public on PubMed Central no later than 12 months after publication.  
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/  
• NIH Off ice of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supported by the NIH must be registered on ClinicalTrials.gov, no later than 21 days after the enrollment of the first subject . Results of all 
clinical trials supported by the NIH, generally, need to be submitted no later than 12 months following the primary completion date.  A delay of up to 2 years is available for trials that meet 
certain criteria and have applied for certifica tion of delayed posting.  
As part of the result posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this study the responsible party is NIAID/DMID which will register the  study and post 
results.   
The responsible party does not plan to request certification of delayed posting.  
Refer to:  
• Public Law 110-85, Section  801, Clinical Trial Databases  
• 42CFR11 
• NIH NOT -OD-16-149 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  95 
CONFIDENTIAL  
 LITERATURE REFERENCES  
1. Erbelding EJ, Post DJ, Stemmy EJ, et al. A Universal Influenza Vaccine: The Strategic Plan 
for the National Institute of Allergy and Infectious Diseases. J Infect Dis 2018; 218:347-54.  
2. Anderson MJ, Heath RB. Cell mediated immunity in experimental inf luenza and parainfluenza 
infection. Dev Biol Stand 1977; 39:379-83.  
3. Brown TA, Murphy BR, Radl J, Haaijman JJ, Mestecky J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after 
experiment al secondary infection with influenza A virus in humans. J Clin Microbiol 1985; 
22:259- 64. 
4. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:7 75-85. 
5. Clements ML, Snyder MH, Buckler -White AJ, Tierney EL, London WT, Murphy BR. 
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers. J Clin Microbiol 1986; 24:47- 51. 
6. Cretescu  L, Beare AS, Schild GC. Formation of antibody to matrix protein in experimental 
human influenza A virus infections. Infect Immun 1978; 22:322-7.  
7. Dolin R, Richman DD, Murphy BR, Fauci AS. Cell -mediated immune responses in humans 
after induced infection with influenza A virus. J Infect Dis 1977; 135:714-9.  
8. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom 
formation and host defens e. J Clin Invest 1998; 101:643-9.  
9. Jameson J, Cruz J, Ennis FA. Human cytotoxic T -lymphocyte repertoire to influenza A 
viruses. J Virol 1998; 72:8682- 9. 
10. Kasel JA, Alford RH, Knight V, Waddell GH, Sigel MM. EXPERIMENTAL INFECTION OF HUMAN VOLUNTEERS WITH EQUINE INFLUENZA VIRUS. Nature 1965; 206:41-3.  
11. Kasel JA, Couch RB. Experimental infection in man and horses with influenza A viruses. Bull World He alth Organ 1969; 41:447-52.  
12. Rudenko LG, Shadrin AS, Geiker VI, Zibina EA, Zykov MP. Associated seroconversions to 
respiratory viruses in volunteers with experimental influenza infection. Acta Virol 1976; 20:135-
41. 
13. Scheinberg M, Blacklow NR, Goldst ein AL, Parrino TA, Rose FB, Cathcart ES. Influenza: 
response of T -cell lymphopenia to thymosin. N Engl J Med 1976; 294:1208- 11. 
14. Snyder MH, Clements ML, Herrington D, London WT, Tierney EL, Murphy BR. 
Comparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human 
influenza A virus reassortants derived from different avian influenza virus donors. J Clin 
Microbiol 1986; 24:467-9.  
15. Ison MG, Campbell V, Rembold C, Dent J, Hayden FG. Cardiac findings during 
uncomplicated acute inf luenza in ambulatory adults. Clin Infect Dis 2005; 40:415-22.  
16. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral 
neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled 
trials for prophylaxis and treatment. Antivir Ther 2005; 10:901- 10. 
17. Nicholson KG, Webster RG, Hay AJ. Textbook of influenza: Blackwell Science Ltd, 1998. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  96 
CONFIDENTIAL  18. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza -specific CD4+ T cells correlate 
with disease protect ion against influenza challenge in humans. Nat Med 2012; 18:274-80.  
19. Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human 
challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug 
study. Clin Infe ct Dis 2015; 60:693-702.  
20. Memoli MJ, Shaw PA, Han A, et al. Evaluation of Antihemagglutinin and 
Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy 
Human Challenge Model. MBio 2016; 7:e00417-16.  
21. Park JK, Han  A, Czajkowski L, et al. Evaluation of Preexisting Anti-Hemagglutinin Stalk 
Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus. MBio 2018; 9.  
22. Memoli MJ, Han A, Walters KA, et al. Influenza A Reinfectio n in Sequential Human 
Challenge: Implications for Protective Immunity and "Universal" Vaccine Development. Clin Infect Dis 2019. 
23. Powers JH, 3rd, Bacci ED, Guerrero ML, et al. Reliability, Validity, and Responsiveness of 
InFLUenza Patient -Reported Outcome (FLU -PRO(c)) Scores in Influenza -Positive Patients. 
Value Health 2018; 21:210-8.  
24. Treanor JJ, Betts RF, Erb SM, Roth FK, Dolin R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans . J Infect Dis 
1987; 156:379-83.  
25. Treanor JJ, Roth FK, Betts RF. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J Clin Microbiol 1990; 28:596-9.  
26. Clements ML, Murphy BR. Development and persistence of local and systemic antibody 
responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin 
Microbiol 1986; 23:66-72.  
27. Betts RF, Douglas RG, Jr., Murphy BR. Resistance to challenge with influenza A/Hong 
Kong/123/77 (H1N1) wild-type virus induced by live attenuated A/Hong Kong/123/77 (H1N1) 
cold-adapted reassortant virus. J Infect Dis 1985; 151:744-5.  
28. Youngner JS, Treanor JJ, Betts RF, Whitaker -Dowling P. Effect of simultaneous 
administration of cold -adapted and wild-type influenz a A viruses on experimental wild -type 
influenza infection in humans. J Clin Microbiol 1994; 32:750-4.  
29. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents 
Chemother 1994; 38:1178-81.  
30. Sears SD, Clements ML, Betts RF, Maassab HF, Murphy BR, Snyder MH. Comparison of 
live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses 
and inactivated virus vaccine in adults. J Infect Dis 1988; 158:1209- 19. 
31. Sears SD, Clements ML. Protective efficacy of low -dose amantadine in adults challenged 
with wild -type influenza A virus. Antimicrob Agents Chemother 1987; 31:1470-3.  
32. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of 
the neuraminidase inhibitor GG167 in experimental human influenza. Jama 1996; 275:295-9.  
33. Reuman PD, Bernstein DI, Keely SP, Young EC, Sherwood JR, Schiff GM. Differential 
effect of amantadi ne hydrochloride on the systemic and local immune response to influenza A. J 
Med Virol 1989; 27:137-41.  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  97 
CONFIDENTIAL  34. Al -Nakib W, Higgins PG, Willman J, et al. Prevention and treatment of experimental 
influenza A virus infection in volunteers with a new antiviral ICI 130,685. J Antimicrob 
Chemother 1986; 18:119-29.  
35. Snyder MH, Betts RF, DeBorde D, et al. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 1988; 62:488-9 5. 
36. Clements ML, Subbarao EK, Fries LF, Karron RA, London WT, Murphy BR. Use of single -
gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol 
1992; 30:655-62.  
37. Clements ML, Snyder MH, Sears SD, Maassab HF, Murphy BR. Evaluation of the 
infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 
reassortant virus vaccine in adult volunte ers. J Infect Dis 1990; 161:869-77.  
38. Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated 
cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in 
susceptible adults. J Infect Dis 1993; 167:305-11.  
39. Treanor JJ, Betts R F. Evaluation of live attenuated cold -adapted influenza B/Yamagata/16/88 
reassortant virus vaccine in healthy adults. J Infect Dis 1993; 168:455-9.  
40. Food and Drug Administration. Highlights of Prescribing Information. Available at: https://www.accessdat a.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf. Accessed 7 June 
2019.  
41. Powers JH, Guerrero ML, Leidy NK, et al. Development of the Flu- PRO: a patient-reported 
outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis 2016; 16:1.  
42. Takashita E, Morita H, Ogawa R, et al. Susceptibility of Influenza Viruses to the Novel Cap-
Dependent Endonuclease Inhibitor Baloxavir Marboxil. Frontiers in Microbiology 2018; 9.  
43. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistanc e in influenza A 
virus: the epidemiology and management. Infect Drug Resist 2017; 10:121- 34. 
44. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory 
requirements. Nat Methods 2015; 12:357-60.  
45. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning 
sequence reads to genomic features. Bioinformatics 2014; 30:923- 30. 
46. Aken BL, Achuthan P, Akanni W, et al. Ensembl 2017. Nucleic Acids Res 2017; 45:D635-
d42. 
47. Robinson MD, Oshlack A. A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol 2010; 11:R25.  
48. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics 2010; 26:139-40.  
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful 
approach to multiple testing. Journal of the Royal statistical society: series B (Methodological) 
1995; 57:289-300.  
50. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical 
clustering. Bioinformatics 2006; 22: 1540-2.  
51. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27:1739 -40. 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  98 
CONFIDENTIAL  52. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids R es 
2000; 28:27-30.  
53. Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses derived 
from a systems biology study of five human vaccines. Nat Immunol 2014; 15:195-204.  
54. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA -seq: 
accounting for selection bias. Genome Biol 2010; 11:R14.  
55. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via 
Coordinate Descent. J Stat Softw 2010; 33:1 -22. 
56. Centers for Disease Control and Prevention. People at High Risk For Flu Complications. 
Available at: https://www.cdc.gov/flu/highrisk/index.htm. Accessed 10 June 2019.  
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  99 
CONFIDENTIAL  
 APPENDICES  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  100 
CONFIDENTIAL  
 Schedule of Events   
Table 12: Schedule of Events  
Evaluation  
Enrollment/Screening  
Study Visit 00A Day -30 to -3 
Inpatient Study Visit 00B Day -2 
Inpatient Study Visit 00C Day -1 
Inpatient Study Visit 1 Day 1  
Inpatient Study Visit 2 Day 2  
Inpatient Study Visit 3 Day 3  
Inpatient Study Visit 4 Day 4  
Inpatient Study Visit 5 Day 5  
Inpatient Study Visit 6 Day 6  
Inpatient Study Visit 7 Day 7  
Inpatient Study Visit 8 Day 8  
Follow -up Study Visit 9 Day 15±3  
Follow -up Study Visit 10 Day 29±3  
Follow -up Study Visit 11 Day 61±5  
Final Study Visit 12 Day 91 ± 7  
Early Termination Visit  
Unscheduled Visit  
Visit type1 c i i i i i i i i i i c c c p c c 
Screening for eligibility  x                 
Signed informed consent  x                 
Review/confirm eligibility criteria  x2 x x x              
Review/confirm informed consent   x3  x              
Inpatient period   x4 x x x x x x x x x       
Discharge from inpatient            x5       
Treatment with antiviral            x6       
Demographics  x                 
Medical History  x x  x              
Height measurements  x7                 
Weight measurements  x7 x7                
Concomitant medications x x x x x x x x x x x x x x  x X 
Physical Exam x                 
Targeted physical exam8  x x x x x x x x x x x x x  x22
 x22 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  101 
CONFIDENTIAL  Evaluation  
Enrollment/Screening  
Study Visit 00A Day -30 to -3 
Inpatient Study Visit 00B Day -2 
Inpatient Study Visit 00C Day -1 
Inpatient Study Visit 1 Day 1  
Inpatient Study Visit 2 Day 2  
Inpatient Study Visit 3 Day 3  
Inpatient Study Visit 4 Day 4  
Inpatient Study Visit 5 Day 5  
Inpatient Study Visit 6 Day 6  
Inpatient Study Visit 7 Day 7  
Inpatient Study Visit 8 Day 8  
Follow -up Study Visit 9 Day 15±3  
Follow -up Study Visit 10 Day 29±3  
Follow -up Study Visit 11 Day 61±5  
Final Study Visit 12 Day 91 ± 7  
Early Termination Visit  
Unscheduled Visit  
Vital signs9 x x x x x x x x x x x x x x  x22
 x22 
SpO 210 x x x x x x x x x x x       
Influenza Challenge     x              
Flu-PRO Survey Instrument    x11 x x x x x x x x     x11 x11 
Collect Flu -PRO Survey Instrument             x      
Adverse event review12    x x x x x x x x x x   x22 x22 
SAE review     x x x x x x x x x x x x x X 
ECG (12 lead) x13        x13         
CXR (PA and lateral)  x                 
Blood for HIV, HBV, HCV  x                 
Serum HCG  x                 
Urine HCG14 x x                
Urine toxicology15 x x                
Blood for Safety Lab Evaluations (Screen)16 x                 
Blood for Safety Lab Evaluations (Follow -up)17     x  x    x     x22  
Sera for cytokine and/or antibody assays18  x   x  x  x  x x x x    
Blood for ASC (ELISpot; fresh PBMC)19       x  x  x       
Blood for innate and/or T and B immunophenotyping 
(cryopreserved  PBMC)19  x     x  x  x x x x    
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  102 
CONFIDENTIAL  Evaluation  
Enrollment/Screening  
Study Visit 00A Day -30 to -3 
Inpatient Study Visit 00B Day -2 
Inpatient Study Visit 00C Day -1 
Inpatient Study Visit 1 Day 1  
Inpatient Study Visit 2 Day 2  
Inpatient Study Visit 3 Day 3  
Inpatient Study Visit 4 Day 4  
Inpatient Study Visit 5 Day 5  
Inpatient Study Visit 6 Day 6  
Inpatient Study Visit 7 Day 7  
Inpatient Study Visit 8 Day 8  
Follow -up Study Visit 9 Day 15±3  
Follow -up Study Visit 10 Day 29±3  
Follow -up Study Visit 11 Day 61±5  
Final Study Visit 12 Day 91 ± 7  
Early Termination Visit  
Unscheduled Visit  
Blood for T and B immunology (cryopreserved 
PBMC)   x     x  x  x x x x  x22 x22 
Blood for transcriptomics (whole blood)   x  x20 x  x    x x    x22 x22 
NP swab for qualitative & quantitative respiratory 
i i21  x x  x x x x x x x       
NLF for cytokine and/or antibody assays   x   x  x  x  x x x x  x22 x22 
NLF for other immunology (immunophenotyping)   x   x  x  x  x     x22 x22 
HLA Typing               x  x22 x22 
 
1. Visit type: c=clinic, i=inpatient unit, p=phone call  
2. Eligibility criteria may change from the day of enrollment to Day -3. To avoid admitting subjects with new exclusion criteria into the inpatient unit, the eligibility criteria 
will be reviewed and confi rmed before  the inpatient stay.  
3. Subjects will have approximately a 48- hour window to decide if they would like to drop out of the study and leave the inpatient unit before challenge virus is 
administered.  
4. Eligible subjects w ill be admitted to the inpatient unit on Day -2 (which is two days prior to the planned challenge) . 
5. Subjects will remain in the inpatient unit for a minimum of seven days after the date of challenge. Subjects will leave the unit after they meet the following discharge 
criteria: two consecutive negative NP swabs (that are performed on Day 7 or thereafter) for influenza A by qualitative RT -PCR performed by the local clinical 
laboratory, are afebrile, have SpO 2≥95% on room air, show no moderate or severe influenza signs or symptoms by clinical evaluation, and are clinically and 
hemodynamically stable for 48 hours. Subjects who do not meet discharge criteria on Day 8 will remain in the inpatient unit until the crite ria are met. Study procedures 
for the inpatient unit will be the same as on Day 8, except for  no additional blood draws unless  clinically indicated.  
6. A single dose of baloxavir marboxil will be offered to all subjects who do not have two consecutive negativ e NP swabs (on Day 7 or thereafter) for influenza A by 
qualitative RT -PCR .  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  103 
CONFIDENTIAL  7. Height and weight will be measured at initial Screening. Weight will be documented a second time on admission to the inpatien t unit. BMI calculation for the purpose of 
Eligibility will be based on the first measured weight. BMI for the purpose of analyses will be calculated with the second measured weight.  
8. Clinical evaluation (including lung, heart, oral/pharyngeal, and neck exams), and symptom evaluation daily while in the inpat ient unit.  
9. Oral temperature, blood pressure, pulse, and respiratory rate  will be assessed three times per day  while the subjects are awake, and as clinically indicated . 
10. Peripheral mixed venous oxygen saturation (SpO 2) on room air at screening, on admission, a nd when oral temperature, blood pressure, pulse, and respiratory rate are 
assessed through the inpatient stay. 
11. Training on Flu- PRO Survey Instrument and Validation Diary for evaluation of severity score. Self -assessment using Flu -PRO and diary to be performed in the morning 
pre-challenge on Day 1, and at approximately 5 PM  through day 14 during the inpatient stay and following discharge to home.  
12. Unsolicited AEs will be m onitored for approximately 30 days post challenge. Review of Flu -PRO for indicators of possible severe influenza associated illness (signs, 
symptoms, or lab findings) not consistent with MMID.  
13. ECG to be performed at screening, on Day 6, and as clinically i ndicated. VTEU sites will consult a cardiologist if ECG is abnormal to determine clinically necessary 
work up.  
14. Among female subjects of childbearing potential, a repeat urine pregnancy test will be performed locally before CXR performed if > 7 days have passed since the 
negative serum pregnancy test was drawn.  
15. Negative drug urine toxicology result (amphetamines, cocaine, and opiates, ) required on screening performed at the Central Lab, and (amphetamines, cocaine, opiates, 
and cannabinoids) on admission to the challenge unit  performed locally . 
16. Screening Safety Labs: white blood cells (WBCs), absolute lymphocyte count, hemoglobin, platelets, alanine transaminase (ALT) , and creatinine (Cr).  
17. Follow -Up Safety Labs: Days 2, 4, and 8, and as clinically indicated: white blood cells (WBCs), absolute lymphocyte count, hemoglobin, platelets, and alanine 
transaminase (ALT), and creatinine (Cr).  
18. Including HAI, MN and NAI antibody titers at admission to the inpatient unit (Day -2) and Visits 8,10 and 11.  
19. Will be drawn from at least a subset of participants for local testing  
20. Blood draw to occur prior to challenge  
21. Multiplex respiratory virus assay to be performed at each site. Positive results prior to influenza virus challenge will result in subject exclusion from the stu dy. No 
respiratory virus testing will be done on the day of challenge.  
22. If indicated.  
 
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  104 
CONFIDENTIAL  
 Venipuncture Volumes  (mL) 
Table 13: Venipuncture Volumes  (all volumes are approximate)  
Evaluation  
Enrollment/Screening  
Study Visit 00A Day -30 to -3 
Inpatient Study Visit 00B Day -2 
Inpatient Study Visit 00C Day -1 
Inpatient Study Visit 1 Day 1  
Inpatient Study Visit 2 Day 2  
Inpatient Study Visit 3 Day 3  
Inpatient Study Visit 4 Day 4  
Inpatient Study Visit 5 Day 5  
Inpatient Study Visit 6 Day 6  
Inpatient Study Visit 7 Day 7  
Inpatient Study Visit 8 Day 8  
Follow -up Study Visit 9 Day 15± 3 
Follow -up Study Visit 10 Day 29±3  
Follow -up Study Visit 11 Day 61±5  
Final Study Visit 12 Day 91  ± 7 
Total Volumes  
Blood for Safety Lab Evaluations (Screen)  151               15 
Blood for Safety Lab Evaluations (Follow -up)     102  102    102     30 
Blood for HLA typing               03  0 
Sera for antibody and cytokine assays   204,5   55  55  55  204,5 55 204 204  100 
Bloo d for ASC (ELISpot; fresh PBMC)6       157  157  157     45 
Blood for innate and/or T and B 
immuno phenotyping ( cryopreserved  PBMC) 6  88,9     88,9  88,9  88,9 88,9 89 89  56 
Blood for T and B immunology (cryopreserved 
PBMC)   4810     3210  3210  3210 4010 4010 4010  264 
Bloo d for transcriptomics (whole blood)   2.5  2.511 2.5  2.5    2.5 2.5    15 
Total (fresh PBMC subset)  15 78.5 0 2.5 17.5 0 72.5 0 60 0 87.5 55.5 68 68 0 525 
Total (subset without fresh PBMC)  15 78.5 0 2.5 17.5 0 57.5 0 45 0 72.5 55.5 68 68 0 480 
 
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  105 
CONFIDENTIAL  1. Safety Lab Evaluations (Screen): Hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti -HCV), human immunodeficiency virus (HIV) testing, and serum 
HCG (for women subjects of childbearing potential), white blood cells (WBCs), absolute lymphocyte  count, hemoglobin, platelets, and alanine transaminase (ALT), and 
creatinine (Cr).   
2. Blood for Safety Lab Evaluations (Follow -up): white blood cells (WBCs), absolute lymphocyte count, hemoglobin, platelets, and alanine transaminase (ALT), and 
creatinine (C r).  
3. HLA testing may be performed on blood already drawn up to this timepoint with no increase in blood volume drawn 
4. Sera tested for antibodies  
5. Sera tested for cytokines  
6. Blood draw and testing will be done in at least a subset of participants  
7. A/Bethesda/MM 2/H1N1 -specific plasmablast  responses (ASC) H1 and N1  
8. Immunophenotyping of innate cells  
9. Immunophenotyping of T and B cell subsets (including cTfh)   
10. A/Bethesda/MM2/H1N1 -specific responses in T and B cell subsets (including cTfh ) 
11. Drawn prechallenge 
 
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  106 
CONFIDENTIAL  
 High -Risk Medical Conditions for Severe Influenza  
People with any of the following medical conditions  are at increased risk for serious 
complications from influenza virus infection [56]. 
• Asthma  
• Neurologic and neurodevelopment conditions  
• Blood disorders (such as sickle cell disease)  
• Chronic lung disease (such as chronic obstructive pulmonary disease [COPD] and cystic 
fibrosis)  
• Endocrine disorders (such as diabetes mellitus)  
• Heart disease (such as congenital heart disease, congestive heart failure and coronary artery disease)  
• Kidney disorders  
• Liver disorders  
• Metabo lic disorders (such as inherited metabolic disorders and mitochondrial disorders)  
• Obesity  with a body mass index [BMI] of 40 or higher  
• Weakened immune system due to disease (such as people with HIV or AIDS, or some 
cancers such as leukemia) or medications (such as those receiving chemotherapy or 
radiation treatment for cancer, or persons with chronic conditions requiring chronic corticosteroids or other drugs that suppress the immune system)  
• Pregnant women  
  
DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  107 
CONFIDENTIAL  
 Flu-PRO Survey Instrument  and Validation Diary 
 

DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  108 
CONFIDENTIAL   
  

DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  109 
CONFIDENTIAL    

DMID Protocol 18- 0010 Version 3.0 
H1N1v Virus Challenge Study in Healthy Subjects  04 November 2020  
 
 
DMID/NIAID/NIH  110 
CONFIDENTIAL   
